

CURRICULUM VITAE OF BENJAMIN WEISS

DATE AND PLACE OF BIRTH: January 26, 1937
Bronx, New York

E-MAIL: ben@benweiss.org

WEB SITE: <http://www.historicalartmedals.com/>

EDUCATION

1958 B.S.	Philadelphia College of Pharmacy and Science, Philadelphia, PA with Distinction (Pharmacy)
1960 M.S. (Pharmacology)	Philadelphia College of Pharmacy and Science, Philadelphia, PA
1963 Ph.D. (Pharmacology)	Philadelphia College of Pharmacy and Science, Philadelphia, PA
1963-1965 (Postdoctoral Fellowship)	National Heart Institute, National Institutes of Health, Bethesda, MD (with Dr. B. B. Brodie)

PROFESSIONAL APPOINTMENTS

1965-1966	Staff Fellow, Laboratory of Chemical Pharmacology, National Heart Institute, National Institutes of Health, Bethesda, MD
1966-1968	Research Associate, Department of Pharmacology, College of Physicians and Surgeons, Columbia University, New York, NY (with Dr. E. Costa)
1968-1971	Pharmacologist, Laboratory of Preclinical Pharmacology, National Institute of Mental Health, St. Elizabeths Hospital, Washington, DC
1971-1972	Chief, Section on Neuroendocrinology, National Institute of Mental Health, Washington, DC

- 1972-2000 Professor of Pharmacology, Medical College of Pennsylvania, Philadelphia, PA
- 1981-1982 Visiting Scientist, Istituto di Ricerche Farmacologiche "Mario Negri," Milan, Italy
- 1981-1998 Chief, Division of Neuropsychopharmacology, Medical College of Pennsylvania, Philadelphia, PA
- 1982 Visiting Scientist, Weitzman Institute of Science, Rehovot, Israel
- 1983-2000 Professor of Psychiatry, Medical College of Pennsylvania, Philadelphia, PA
- 2000-Present Emeritus Professor of Pharmacology and Physiology, Drexel University College of Medicine, Philadelphia, PA.

HONORS AND AWARDS

- 1958 Gold Medal for Attaining Highest Scholastic Average of College Graduates
- 1958 Joseph W. E. Harrison Award for Excellence in Pharmacology
- 1958 Frederick William Haussman Memorial Prize
- 1958 Dobbins Scholarship
- 1959 Rexall Award
- 1959 Borden Award
- 1959 Rho Chi Honorary Pharmaceutical Society
- 1980 Christian R. and Mary F. Lindback Award for Distinguished Teaching
- 1981 Named as one of the Top One Thousand Most Quoted Scientists in the World.
- 1982 Research Medal awarded by the University of Milan, Milan, Italy
- 1986 MERIT Award - National Institute of Mental Health
- 1995 Award from China Bureau of Foreign Experts Affairs, Suzhou Medical College, Suzhou, China as Outstanding Scientist
- 2000 Emeritus Professorship- Drexel University College of Medicine

MEMBERSHIPS IN PROFESSIONAL AND SCIENTIFIC SOCIETIES

- American Society for Neurochemistry
- American Society for Pharmacology and Experimental Therapeutics (Emeritus)
- American College of Neuropsychopharmacology (Emeritus)
- International Brain Research Organization
- American Association of University Professors
- Society for Neuroscience
- British Brain Research Association
- European Brain and Behavior Society
- International Society for Neurochemistry
- Gerontological Society of America

EDITORIAL AND CONSULTANT POSITIONS

Books Published:

Editor: Cyclic Nucleotides in Disease, University Park Press, Baltimore, MD. 1975

Editor: Antisense Oligodeoxynucleotides and Antisense RNA: Novel Pharmacological and Therapeutic Agents, CRC Press, Boca Raton, FL. 1997

Editorial Advisory Board:

Past: Journal of Pharmacology & Experimental Therapeutics
Neuropharmacology
Journal of Cyclic Nucleotide Research
Life Sciences
Archives Internationales de Pharmacodynamie et de Therapie
Neurochemistry International

Consultant: National Institute of Mental Health
National Institute of Aging
National Science Foundation
Manitoba Health Research Council
Franklin Research Center
Veterans Administration Hospital, Neuropsychopharmacology Unit ICI, Americas
Hoffman-LaRoche, Inc.
Wyeth Laboratories
Smith, Kline and French Laboratories
Information Ventures, Inc. for Molecular Biology: Cyclic Nucleotides
The Upjohn Company
The Cancer Institute of New Jersey

ACADEMIC COMMITTEES

1972-1978 Pharmacology Graduate Committee, Chairman
1973-1978 Committee on Appointments and Promotions, Member
1978-1979 Committee on Appointments and Promotions, Chairman
1972-1984 Fellowships and Awards Committee, Member
1972-1978 Graduate Education Committee, Member
1972-1984 Student Evaluation Committee, Member
1977 President's Award Committee, Chairman
1977 Institutional Self-Study for Accreditation Subcommittee on Faculty, Member
1977 Committee on Graduate Courses, Chairman
1977-1978 Committee to Devise a Faculty Handbook, Member
1980 Microbiology Chairman Search Committee, Member

1981-1986 Executive Committee of the Faculty, Member
 1982 Committee on Faculty Communications, Member
 1983 Finances/Physical Plant Subcommittee, Member
 1983 Ad Hoc Committee to Evaluate Criteria for Tenure, Member
 1983-1986 EPPI Subcommittee on Mental Health and Neurosciences of the Executive Faculty of MCP, Member
 1983-1989 Multidisciplinary Research Committee, Member
 1983-1988 Analytical Laboratory Supervisory Committee, Member
 1985-1990 Radiation Safety Committee, Member
 1985-1989 Tenure Committee, Member
 1989-1992 Molecular Biology Core Laboratory Committee, Member
 1989 Tenure Committee, Chairman
 1989 Committee to Review the Department of Anesthesia, Chairman
 1990-1995 Grievance Committee, Member
 1990-1994 Committee on Appointments and Promotions, Member
 1990 Executive Committee of the Faculty, Member
 1991-1994 Hearing Committee for Tenured Faculty, Member
 1991-1993 Faculty Development Committee of Board of Directors, Member
 1993-1995 Faculty Grievance Committee, Chairman
 1994-1995 Graduate School Faculty Affairs Committee, Member
 1994-1995 Graduate School By Laws Committee, Member
 1994-1995 Molecular and Cell Biology Steering Committee, Member
 1995-1999 M.D., Ph.D. Committee, Member
 1997-1999 Allegheny University of the Health Sciences Institute for the Neuroscience Advisory Committee, Member

ADMINISTRATION OF TEACHING PROGRAMS

1972-1978 Pharmacology Graduate Program, Director
 1975-1984 Advanced Topics in Pharmacology - Course Coordinator
 1981-1984 Psychopharmacology Update - Co-Director
 1983-1986 Basic and Clinical Aspects of the Neurosciences - Course Director
 1985-1993 Neuropsychopharmacology Journal Club and Research - Course Director
 1993-1998 Current Topics in the Molecular Basis of Behavior- Course Director

INITIATED AND ORGANIZED NEW COURSES AND PROGRAMS

1972 Pharmacology Graduate Program
 1975 Advanced Topics in Pharmacology
 1975 Cyclic Nucleotide Journal Club
 1975 Pharmacology Seminar Program
 1976 Joint Basic Sciences Seminar Program
 1976 Biomedical Instrumentation and Techniques
 1983 Basic and Clinical Aspects of the Neurosciences

1985 Neuropsychopharmacology Research Club
1993 Current Topics in the Molecular Basis of Behavior

PARTICIPATION IN TEACHING AND TRAINING PROGRAMS

Pharmacology and Experimental Therapeutics - Medical College of Pennsylvania
Biomedical Instrumentation and Techniques - Medical College of Pennsylvania
Advanced Topics in Pharmacology - Medical College of Pennsylvania
Cyclic Nucleotide Journal Club - Medical College of Pennsylvania
Pharmacology Seminar Program - Medical College of Pennsylvania
Basic Sciences Seminar Program - Medical College of Pennsylvania
Molecular Aspects of Cell Structure and Function - Joint Program; Medical College of Pennsylvania and Bryn Mawr College
Neuropharmacology - Joint Program; Medical College of Pennsylvania and Philadelphia College of Pharmacy and Science
Neuropsychopharmacology Colloquium - Joint Program; Medical College of Pennsylvania and University of Pennsylvania
Basic Science Course for Neurology Residents - Medical College of Pennsylvania
Principles in Neurobiology - Mario Negri Research Institute, Milan, Italy
Psychopharmacology Update - Medical College of Pennsylvania
Training Program in Neuropsychopharmacology - Member of Executive Board, University of Pennsylvania
Neuropsychopharmacology-Neurosurgical Research Training Program - Medical College of Pennsylvania - Director
Anesthesia-Neuropsychopharmacology Research Training Program - Medical College of Pennsylvania - Director
Initiated and effected a formal affiliation between the Medical College of Pennsylvania and the University of Milan
Sandoz-Dorsey Teaching Program - Medical College of Pennsylvania

EXTRAMURAL RESEARCH SUPPORT

Source of Support: National Institute of Health
Title: Research Fellowship
Sponsor: Benjamin Weiss, Ph.D.
Period of Support: 6/19/75 - 6/18/76
Direct Costs: \$13,000

Source of Support: Scottish Rite Schizophrenia Research Program
Title: The Role of Cyclic Nucleotides in Schizophrenia
Principal Investigator: Benjamin Weiss, Ph.D.
Period of Support: 4/1/74 - 3/31/76
Direct Costs: \$35,722

Source of Support: National Institute of Health
Title: Research Fellowship (HL-01839)
Sponsor: Benjamin Weiss, Ph.D.
Period of Support: 9/1/74 - 8/31/76
Direct Costs: \$26,400

Source of Support: National Cancer Institute
Title: Agents Inhibiting Phosphodiesterase of Cancer Cells (CA 15883)
Principal Investigator: Benjamin Weiss, Ph.D.
Period of Support: 5/1/74 - 7/31/77
Direct Costs: \$143,538

Source of Support: National Institute of Aging
Title: Effect of Age on the Ability of Organs to Develop a Denervation
Supersensitivity of the Membrane Bound Cyclic 3',5'-AMP System
(AG00003)
Principal Investigator: Benjamin Weiss, Ph.D.
Period of Support: 6/1/76 - 5/31/80
Direct Costs: \$89,157

EXTRAMURAL RESEARCH SUPPORT (continued)

Source of Support: National Institute of Neurological and Communicative Disorders and Stroke
Title: Influence of Neuronal Activity on the Development of Postjunctional Receptors (NS13768)
Principal Investigator: Benjamin Weiss, Ph.D.
Period of Support: 7/1/77 - 6/31/80
Direct Costs: \$116,544.

Source of Support: National Institute of Mental Health
Title: Psychotropic Drugs and Cyclic Nucleotide Metabolism (MH30096)
Principal Investigator: Benjamin Weiss, Ph.D.
Period of Support: 8/1/77 - 7/31/80
Direct Costs: \$117,548

Source of Support: National Institute of Neurological and Communicative Disorders and Stroke
Title: Development and Regeneration of the Nervous System (NS07061)
Co-Investigator: Benjamin Weiss, Ph.D.
Period of Support: 7/1/78 - 6/31/81
Direct Costs: \$174,684

Source of Support: Scottish Rite Schizophrenia Research Program
Title: Research Fellowship
Sponsor: Benjamin Weiss, Ph.D.
Period of Support: 1979
Direct Costs: \$6,000

Source of Support: National Institute of Neurological and Communicative Disorders and Stroke
Title: Regulation of Brain Aminergic Receptors in Aging (NS16242)
Principal Investigator: Benjamin Weiss, Ph.D.
Period of Support: 4/1/80 - 3/31/84
Direct Costs: \$215,585

Source of Support: National Institute of Mental Health
Title: Psychotropic Drugs and Cyclic Nucleotide Metabolism (MH30096)
Principal Investigator: Benjamin Weiss, Ph.D.
Period of Support: 8/1/80 - 1/31/85
Direct Costs: \$204,557

EXTRAMURAL RESEARCH SUPPORT (continued)

Source of Support: Scottish Rite Schizophrenia Research Program
Title: Interaction of Neuropeptides with Calmodulin
Principal Investigator: Benjamin Weiss, Ph.D.
Period of Support: 8/1/81 - 7/31/83
Direct Costs: \$44,370

Source of Support: National Institute of Mental Health
Title: Training Program in Neuropsychopharmacology
Preceptor: Benjamin Weiss, Ph.D.
Period of Support: 7/1/82 - 6/30/85
Direct Costs: \$298,684

Source of Support: National Research Service Award
Title: Pineal Gland and Melatonin During Reproductive Aging (AG05321)
Sponsor: Benjamin Weiss, Ph.D.
Period of Support: 9/1/83 - 8/31/84
Direct Costs: \$20,040

Source of Support: National Institute on Aging
Title: Pineal beta Receptors and Melatonin During Reproductive Aging (AG04858)
Co-Investigator: Benjamin Weiss, Ph.D.
Period of Support: 9/1/84 - 8/31/85
Direct Costs: \$15,000

Source of Support: National Institute on Aging
Title: Role of SCN: Serotonin in Female Reproductive Aging (AG02867)
Co-Investigator: Benjamin Weiss, Ph.D.
Period of Support: 7/1/85 - 3/31/87
Direct Costs: \$96,478

Source of Support: NATO Advanced Study Institute
Title: Principles and Clinical Implications of Neuroreceptor Modulation
Principal Investigator: Benjamin Weiss
Period of Support: 1/1/86 - 6/30/87
Direct Costs: \$40,000

EXTRAMURAL RESEARCH SUPPORT (continued)

Source of Support: Hereditary Disease Foundation
Title: Plasticity of Gene Expression in the Basal Ganglia
Co-investigator: Benjamin Weiss, Ph.D.
Period of Support: 3/1/86 - 2/28/87
Direct Costs: \$14,974

Source of Support: National Institute of Mental Health
Title: Plasticity of Gene Expression in the Basal Ganglia (MH41714)
Co-investigator: Benjamin Weiss, Ph.D.
Period of Support: 8/1/86 - 7/31/87
Direct Costs: \$14,974

Source of Support: National Institute of Mental Health
Title: Role of Calmodulin in Chronic Cocaine-Induced Behaviors (DA04427)
Principal Investigator: Benjamin Weiss, Ph.D.
Period of Support: 7/1/87 - 6/30/88
Direct Costs: \$14,959

Source of Support: National Research Service Award
Title: Role of Calmodulin in Chronic Cocaine-Induced Behaviors (DA05318)
Sponsor: Benjamin Weiss, Ph.D.
Period of Support: 7/1/87 - 6/30/89
Direct Costs: \$39,000

Source of Support: National Institute of General Medical Sciences
Title: Regulation of Calmodulin - Dependent Processes (GM34334)
Principal Investigator: Benjamin Weiss, Ph.D.
Period of Support: 7/1/86 - 12/31/89
Direct Costs: \$231,323

Source of Support: National Institute of Mental Health (MERIT Award)
Title: Behavioral & Biochemical Correlates of Dopamine Responses (MH42148)
Principal Investigator: Benjamin Weiss, Ph.D.
Period of Support: 8/1/87 - 7/31/91
Direct Costs: \$404,648

EXTRAMURAL RESEARCH SUPPORT (continued)

Source of Support: Allegheny-Singer Research Institute
Title: Reversal of Dopaminergic Supersensitivity: Preclinical Mechanisms and Clinical Applications
Principal Investigator: Benjamin Weiss, Ph.D.
Period of Support: 7/1/90 - 6/30/93
Direct Costs: \$254,415

Source of Support: National Institute of Mental Health (MERIT Award)
Title: Behavioral & Biochemical Correlates of Dopamine Responses (MH42148)
Principal Investigator: Benjamin Weiss, Ph.D.
Period of Support: 8/1/91 - 7/31/95
Direct Costs: \$420,945

Source of Support: Allegheny Singer Research Institute
Title: Antisense RNA Vector Reduces Expression of D2 Receptors
Principal Investigator: Benjamin Weiss, Ph.D.
Period: 4/1/96-3/31/97
Direct Costs: \$25,816

Source of Support: National Institute of Neurological Disorders and Stroke
Title: Role of Calmodulin in Neuronal Differentiation (NS 30724)
Principal Investigator: Benjamin Weiss, Ph.D.
Period of Support: 9/1/93 - 8/31/97
Direct Costs: \$357,585

Source of Support: National Institute of Mental Health
Title: Behavioral & Biochemical Correlates of Dopamine Responses (MH42148)
Principal Investigator: Benjamin Weiss, Ph.D.
Period of Support: 4/1/95 - 3/31/99
Direct Costs: \$386,288

PATENTS

Title: Administration of Oligonucleotides Antisense to Dopamine Receptor mRNA for Diagnosis and Treatment of Neurological Pathologies

Inventor: Benjamin Weiss

Patent Number: 5,840,708

Title: Compositions and Methods to Regulate Calmodulin Gene Expression and Uses Thereof for Influencing Cell Growth and Differentiation

Inventor: Benjamin Weiss

Patent Number: 08/748,104

Title: Methods and Compositions for Diagnosis and Treatment of Pathological Conditions Related to Abnormal Dopamine Receptor Expression

Inventor: Benjamin Weiss

Patent Number: 08/816,426

POSTDOCTORAL STUDENTS AND VISITING SCIENTISTS TRAINED

1. Anthony Kidman, Ph.D.
Postdoctoral Training: 1969-1971
Current Position: The New South Wales Institute of Technology
New South Wales, Australia
2. John Crayton, M.D.
Postdoctoral Training: 1969-1970
Current Position: Department of Psychiatry
University of Chicago
Chicago, Illinois
3. Samuel J. Strada, Ph.D.
Ph.D. (Pharmacology), 1970
Postdoctoral Training: Vanderbilt University
1970-1972
Current Position: Associate Dean for Research
University of Southern Alabama
Mobile, Alabama

4. Petko Uzunov, M.D.
Postdoctoral Training: 1970-1972
Current Position: Professor and Chairman,
Department of Pharmacology
President, Bulgarian Medical Academy
Sofia, Bulgaria

5. Michael Ebadi, Ph.D.
Postdoctoral Training: 1970-1972
Current Position: Professor and Chairman
Department of Pharmacology
University of Nebraska Medical Center
Omaha, Nebraska

6. Thomas Tulenko, Ph.D.
Ph.D. (Physiology), 1972
Postdoctoral Training: Boston University
1972-1977
Current Position: Professor of Physiology
Dept. of Physiol./Biochem.
Medical College of PA.
Philadelphia, Pennsylvania

7. Robert Levin, Ph.D.
Ph.D. (Pharmacology), 1974
Postdoctoral Training: University of Pennsylvania
1974-1976
Current Position: Professor
University of Buffalo

8. Richard Fertel, Ph.D.
Ph.D. (Pharmacology), 1972
Postdoctoral Training: Washington University
1972-1975
Current Position: Associate Professor
Department of Pharmacology
University of Ohio
Columbus, Ohio

9. Louise H. Greenberg, Ph.D.
Ph.D. (Pharmacology), 1974
Postdoctoral Training: Bryn Mawr College
1974-1977
Current Position: Visiting Assist. Professor
Department of Pharmacology
Medical College of PA.
Philadelphia, Pennsylvania

10. Walter C. Prozialeck, Ph.D.
Ph.D. (Pharmacology), 1978
Postdoctoral Training:
Current Position:
- Jefferson University
1978-1980
Chairman, Department of Pharmacology
Chicago Col. of Osteopathic Medicine
Chicago, Illinois
11. Mauro Cimino, D. Biol.
Postdoctoral Training:
Current Position:
- 1979
- The University of Milan
Milan, Italy
12. M. Blair Clark, Ph.D.
Ph.D. (Anatomy), 1979
Postdoctoral Training:
Current Position:
- Tulane University
1979-1982
Assistant Professor
Department of Anatomy
University of Maryland
School of Medicine
Baltimore, Maryland
13. Mary Sellinger-Barnette, Ph.D.
Ph.D. (Pharmacology), 1979
Postdoctoral Training:
Current Position:
- University of Pennsylvania
1979-1984
Research Scientist
Smith Kline & French Labs.
Philadelphia, Pennsylvania
14. Judith S. Freilich, M.D.
M.D., 1979
Postdoctoral Training:
Current Position:
- Medical College of PA.
1981-1983
Associate, Univ. of PA.
Philadelphia, Pennsylvania
15. Long-Wu Zhou, M.D., 1958
Postdoctoral Training:
Current Position:
- 1981-1983
Research Assistant Professor
Allegheny University of the Health Sciences
Philadelphia, Pennsylvania

16. Kyriaki Thermos, Ph.D.
Ph.D. (Pharmacology), 1984
Postdoctoral Training:
Current Position:
New York University
1984-1986
Associate Professor
Department of Pharmacology
University of Crete
Heraklion, Crete, Greece
17. Jill Roberts-Lewis, Ph.D.
Ph.D. (Pharmacology), 1986
Postdoctoral Training:
Current Position:
University of Michigan
1986-1988
Research Scientist
Cephalon, Inc.
145 Brandywine Parkway
West Chester, Pennsylvania
18. Jo Elia, M.D.
M.D., 1982
Postdoctoral Training:
Current Position:
Medical College of PA.
1986
Director of Child Psychiatry
Allegheny University of the Health Sciences
Philadelphia, Pennsylvania
19. David Allen, M.D.
M.D., 1983
Postdoctoral Training:
Current Position:
Temple University
1984-1985
Staff Neurosurgeon
Reading Hospital and Medical Center
Reading, PA
20. Jiang Fan Chen, M.D.
Postdoctoral Training:
Current Position:
Third Military Medical College, P.R.C.
1987-1989
Assistant Professor
Harvard Medical School
Cambridge, Mass.
21. David Goodale, DDS, PhD
Postdoctoral Training
1987-1989

22. Guang Bai, M.D.
Postdoctoral Training:
Current Position:
 Universitat Ulm
 1988-1991
 Assistant Professor
 Department of Biomedical Sciences
 University of Maryland School of Medicine
 Baltimore, MD
23. Mauro Cimino, D. Biol. Sci
Visiting Scientist:
Current Position:
 University of Rome
 1987-1988
 University of Milan
 Milan, Italy
24. Long-Wu Zhou, M.D., 1958
Visiting Scientist:
Current Position
 Beijing Medical College, P.R.C.
 1988-present
 Research Assistant Professor
 Allegheny University of the Health Sciences
 Philadelphia, Pennsylvania
25. Thomas Connell, M.D.
 Postdoctoral Fellow
Current Position:
 Medical College of Pennsylvania
 1990-1992
 Staff Psychiatrist
 Norristown State Hospital
 Norristown, PA
26. Naoki Natsukari, M.D., Ph.D.
Postdoctoral Fellow
 Hamamatsu School of Medicine, Japan
 1993-1995
27. Genoveva Davidkova, M.D., Ph.D.
Postdoctoral Fellow
Current Position
 Medical Academy, Sofia, Bulgaria
 1994-1997
 Research Associate
 Rockefeller University

GRADUATE STUDENTS TRAINED

1. William Hait, M.D., Ph.D.
Training Period 1972-1976
Degrees attained M.D., Ph.D. (Pharmacology)
Current Position: Director
The Cancer Institute of
New Jersey
New Brunswick, NJ

2. Elinor Cantor, Ph.D.
Training Period 1974-1979
Degree attained Ph.D. (Pharmacology), 1979
Current Position: Senior Research Pharmacologist
Berlex Laboratories
Cedar Knolls, NJ

3. Thomas L. Wallace, Ph.D.
Training Period 1977-1982
Degree attained Ph.D. (Pharmacology), 1982
Current Position: Associate Director, Pharmacology
Triplex Pharmaceuticals
Woodlands, TX

4. Craig Q. Earl, Ph.D.
Training Period 1978-1983
Degree attained Ph.D. (Cell Biology), 1983
Current Position: Assistant Director
CNS Therapeutic Area
Solvay Pharmaceuticals
Marietta, GA

5. James Winkler, Ph.D.
Training period 1981-1986
Degree attained Ph.D. (Pharmacology), 1987
Current Position: Associate Director
Department of Pharmacology
Smith Kline & French Labs.
Philadelphia, Pennsylvania
Visiting Assistant Professor
Department of Pharmacology
Medical College of PA

- | | | |
|----|--|---|
| 6. | Jiang Fan Chen, M.D.
Training period:
Degree attained
<u>Current Position:</u> | 1990-1993
Ph.D. (Pharmacology), 1993
Assistant Professor
Massachusetts General Hospital
Harvard Medical School
Charlestown, MA |
| 7. | Zheng-Hong Qin, M.D.
Training period:
Degree attained:
<u>Current Position:</u> | 1989-1994
Ph.D. (Pharmacology) 1994
Postdoctoral Fellow
National Institute of Mental Health
Bethesda, MD |
| 8. | Wangfang Hao, M.Sc.
Degree attained
Training Period:
<u>Current Position:</u> | M.Sc. (Pharmacology) 1997
1995-1997
Johnson and Johnson Research Laboratories |

MEDICAL STUDENTS TRAINED:

Robert Figlin, M.D.
 Stephen Weiss, M.D.
 Shelly Uram, M.D.
 Eva Gomolinski, M.D.
 Michael Hillman, M.D.
 Jo Ellen Habas, M.D.

PREMEDICAL STUDENTS TRAINED:

Scott Fields
 Gary Koretsky
 David Rubashkin
 Jo Ann Seagraves
 Lisa Ann Brady
 Judy Yuko Kameoka
 Amit Shah

PROFESSIONAL ACTIVITIES AT SYMPOSIA AND CONFERENCES

- Organized symposium: Cyclic Nucleotides in Disease, Philadelphia, PA., 1974
- Organized symposium: Interaction of Calmodulin with Psychotropic Drugs, at the Meeting of the American College of Neuropsychopharmacology, San Juan, Puerto, Rico, 1982
- Organized symposium: Antisense Strategies in Neurobiology, at the XIXth CINP Congress, Washington, DC, 1994

CHAired SCIENTIFIC SESSIONS AT NATIONAL AND INTERNATIONAL MEETINGS AND CONFERENCES

- 1971 Meeting of American Society for Pharmacology and Experimental Therapeutics, Burlington, VT.
- 1972 Meeting of American Chemical Society, Philadelphia.
- 1973 Meeting of Federal of American Societies for Experimental Biology, Atlantic City, NJ.
- 1974 Cyclic Nucleotides in Disease, Philadelphia, PA.
- 1974 Scottish Rite Schizophrenia Research Program, Boston, MA.
- 1975 Gordon Conference on Catecholamines, Andover, NH.
- 1976 Meeting of Federation of American Societies of Experimental Biology, Anaheim, CA.
- 1977 NATO Advanced Study Institute on Cyclic Nucleotides, Tremezzo, Italy.
- 1981 International Symposium on Aging Brain and Ergot Alkaloids, Rome, Italy.
- 1982 International Conference on the Aging of the Brain, Mantua, Italy.
- 1982 Meeting of the American College of Neuropsychopharmacology, San Juan, Puerto Rico.
- 1983 Meeting of the Federation of American Societies for Experimental Biology, Chicago, ILL.
- 1983 Symposium on Altered Endocrine Status During Aging, Fourth Philadelphia Symposium on Aging, Philadelphia, PA.
- 1985 Symposium on Aging of the Brain from Laboratory Animal to Man, IVth World Congress of Biological Psychiatry, Philadelphia, PA.

CHAired SCIENTIFIC SESSIONS AT NATIONAL AND INTERNATIONAL MEETINGS AND CONFERENCES *(continued)*

- 1986 Meeting of Federation of American Societies for Experimental Biology, St. Louis, MO.
- 1987 Meeting of the Society for Neuroscience, New Orleans, LA.
- 1988 Meeting of the American Physiological Society and the American Society for Pharmacology and Experimental Therapeutics, Montreal, Canada
- 1991 Meeting of the Society for Neuroscience, New Orleans, LA
- 1994 Symposium on Antisense Strategies in Neurobiology, XIXth C.I.N.P. Congress, Washington, DC
- 1997 Fourth National Congress of Pharmacology, Sofia, Bulgaria

INVITED SPEAKER AT NATIONAL AND INTERNATIONAL CONFERENCES AND SYMPOSIA

- 1967 Symposium on Biological Role of Indolealkamine Derivatives, New York.
- 1968 Meeting of the American College of Neuropsychopharmacology, San Juan, Puerto Rico.
- 1969 Symposium on Biogenic Amines as Physiological Regulators, Woods Hole, MA.
- 1970 Symposium on the Role of Cyclic AMP in Cell Function, San Diego, CA.
- 1970 Role of Cyclic AMP in Nervous System, Neurosciences Research Program, Boston, MA.
- 1971 Cyclic AMP and Cell Function, New York Academy of Science, New York.
- 1971 First International Conference on the Physiology and Pharmacology of Cyclic AMP, Milan, Italy.
- 1971 Symposium on Fetal Pharmacology, Stockholm, Sweden.
- 1972 Symposium on the Biochemistry and Physiology of the Pineal Gland Bethesda, MD.
- 1973 Third International Catecholamine Symposium, Strasbourg, France.
- 1974 Conference on Cyclic Nucleotides and the Nervous System, St. Odile, France.
- 1974 Gordon Conference on Catecholamines, Brewster, NH.

INVITED SPEAKER AT NATIONAL AND INTERNATIONAL CONFERENCES AND SYMPOSIA

(continued)

- 1974 Second International Conference on Cyclic AMP, Vancouver, Canada.
- 1975 Gerontological Society Symposium on the Pharmacology of Aging Systems, Louisville, KY.
- 1975 Gordon Conference on Catecholamines, Andover, NH.
- 1976 Symposium on Cyclic Nucleotide Systems - A Target for Drug Design, London, England.
- 1977 Gordon Conference on Hormone Action, Palo Alto, CA.
- 1977 Series of Prominent Neuroscientists at University of Pittsburgh, PA.
- 1977 Third International Congress of Cyclic Nucleotides, New Orleans, LA.
- 1977 NATO Advanced Study Institute on Cyclic Nucleotides, Tremezzo, Italy.
- 1978 Gerontology Symposium at the Federation of American Societies for Experimental Biology, Atlantic City, NJ.
- 1978 Fourth International Symposium on Catecholamines, Santa Barbara, CA.
- 1978 Meeting of the American College of Neuropsychopharmacology, Maui, HI.
- 1979 Symposium on Long Term Effects of Neuroleptics, Monte Carlo, Monaco.
- 1979 First International Colloquium on Receptors, Neurotransmitters and Peptide Hormones, Capri, Italy.
- 1979 Symposium on Clinical Implications of Cyclic Nucleotides, Denver, CO.
- 1980 Conference on Calmodulin and Cell Functions, New York Academy of Sciences, New York.
- 1980 Gordon Research Conference on Cyclic Nucleotides, Meriden, NH.
- 1980 New York Academy of Sciences Meeting on the Biology of Aging, New York, NY.
- 1980 International Symposium on the Clinical Pharmacology of Apomorphine and Other Dopaminomimetics, Cagliari, Sardinia, Italy.
- 1981 Symposium on the Pharmacological Implications of Calmodulin, Western Pharmacology Society, Honolulu, HI.

INVITED SPEAKER AT NATIONAL AND INTERNATIONAL CONFERENCES AND SYMPOSIA

(continued)

- 1981 Symposium on the Developmental Neurobiology of the Melatonin Rhythm Generating System, Bethesda, MD.
- 1981 International Symposium on Typical and Atypical Antidepressants, Taormina, Sicily, Italy.
- 1981 Gordon Research Conference on Medicinal Chemistry, Andover, NH.
- 1981 Conference on Dynamics of Neurotransmitter Function, National Institutes of Health, Bethesda, MD.
- 1981 International Symposium on Aging Brain and Ergot Alkaloids, Rome, Italy.
- 1982 International Conference on the Aging of the Brain, Mantua, Italy.
- 1982 Meeting of the American College of Neuropsychopharmacology, San Juan, Puerto Rico.
- 1983 Meeting of the Federation of American Societies for Experimental Biology, Chicago, IL.
- 1983 Falk Symposium on Mechanisms of Hepatocyte Injury and Death, Basel, Switzerland.
- 1983 Annual Meeting of American Chemical Society, White Haven, PA.
- 1983 Symposium on Altered Endocrine Status During Aging; Fourth Philadelphia Symposium on Aging, Philadelphia, PA.
- 1984 International Conference on Calcium Metabolism and Nervous System: The Problem of Spasmophilia, Rome, Italy.
- 1984 First European Meeting on New Trends in Medicine, Milanomedicina, Milan, Italy.
- 1985 Fourth Capo Boi Conference on Neuroscience, Sardinia, Italy.
- 1988 FIDIA Research Foundation Symposium: Neurochemical Pharmacology 1988, Washington, D.C.
- 1988 Meeting of the American Physiological Society and The American Society for Pharmacology and Experimental Therapeutics, Montreal, Canada.
- 1989 Sixth Capo Boi Conference on Neuroscience, Sardinia, Italy.
- 1989 Annual Meeting of the Society for Neuroscience, Phoenix, Arizona.

INVITED SPEAKER AT NATIONAL AND INTERNATIONAL CONFERENCES AND SYMPOSIA

(continued)

- 1990 Symposium on Dopamine Systems and their Regulation, Como, Italy.
- 1994 Symposium on Antisense Strategies in Neurobiology, CINP Congress, Washington, DC.
- 1994 Meeting of the American Psychological Association, Los Angeles, CA.
- 1995 International Symposium on Practical Approaches to the Regulation of Gene Expression: Progress in Neuroscience, University of Oxford, Oxford, England.
- 1995 International Conference on Therapeutic Oligonucleotides from Cell to Man, Seillac, France.
- 1995 Symposium on the Application of Antisense Strategies for Investigation of Receptor Mechanisms in Vivo and In Vitro, Fifty-Seventh Annual Scientific Meeting of The College on Problems of Drug Dependence, Inc., Scottsdale, AZ.
- 1996 New York Academy of Science Symposium on Use of Antisense Oligonucleotides as Pharmacological Tools, New York, NY.
- 1996 INSERM Workshop on Antisense Strategies in the Neurosciences, Paris, France.
- 1997 International Symposium on Antisense Oligonucleotide Gene Knockout in the Nervous System, Oxford, England
- 1997 Conference on Antisense 97: Targeting the Molecular Basis of Disease, Cambridge, MA
- 1997 Plenary Lecture on Antisense RNA Generating Vectors at the Fourth National Congress of Pharmacology, Sofia, Bulgaria
- 1997 Symposium on Antisense Strategies, American College of Neuropsychopharmacology, Hawaii
- 1999 IBC's International Conference on Oligonucleotide Therapeutics, La Jolla CA.

PUBLICATIONS

1. Weiss, B.: The role of unsaturated fats in lowering serum cholesterol levels. Am. J. Pharm. 131:137-151, 1959.
2. Weiss, B.: Dihydrocodeine, a pharmacologic review. Am. J. Pharm. 131:286-301, 1959.
3. Weiss, B. and Ewing, C.G.T.: Anticonvulsant activity of three new dioxolane derivatives. Am. J. Pharm. 131:307-313, 1959.
4. Weiss, B. and Rossi, G.V.: Potentiation of the activity of narcotic analgesics by a trifluorinated phenothiazine. Arch. Intl. Pharmacodyn. 136:336-346, 1962.
5. Weiss, B. and Rossi, G.V.: Separation of catecholamines by paper chromatography. Nature 195:178, 1962.
6. Weiss, B., Rossi, G.V. and Reber, L.A.: A mathematical basis for the solvent-reversal technique of paper chromatography. Nature 197:280-282, 1963.
7. Weiss, B. and Rossi, G.V.: Catecholamines: biosynthesis and inhibitors of formation. Am. J. Pharm. 135:206-218, 1963.
8. Weiss, B. and Rossi, G.V.: Metabolism of dopa-¹⁴C in the normal and alpha-methyldopa-treated mouse. Biochem. Pharmacol. 12:1399-1405, 1963.
9. Brodie, B.B., Davies, J.I., Hynie, S., Krishna, G. and Weiss, B.: Interrelationships of catecholamines with other endocrine systems. Pharmacol. Revs. 18:273-289, 1966.
10. Weiss, B., Davies, J.L. and Brodie, B.B.: Evidence for a role of adenosine 3',5'-monophosphate in adipose tissue lipolysis. Biochem. Pharmacol. 15:1553-1561, 1966.
11. Weiss, B. and Costa, E.: Adenyl Cyclase activity in rat pineal gland: Effects of chronic denervation and norepinephrine. Science 156:1750-1752, 1967.
12. Weiss, B.: Discussion of the formation, metabolism and physiologic effects of melatonin. Adv. Pharmacol. 6A:152-155, 1968.
13. Weiss, B. and Maickel, R.P.: Sympathetic nervous control of adipose tissue lipolysis. Intl. J. Neuropharmacol. 7:395-405, 1968.
14. Weiss, B. and Costa, E.: Selective stimulation of adenyl cyclase of rat pineal gland by pharmacologically-active catecholamines. J. Pharmacol. Exp. Ther. 161:310-319, 1968.

15. Costa, E. and Weiss, B.: The present understanding of subsynaptic and post-junctional monoamine receptors. In: Psychopharmacology - Review of Progress 1957-1967, Superintendent of Documents, 1968. U.S. Printing Office, Washington, D.C., pp. 39-55, 1968.
16. Krishna, G., Weiss, B. and Brodie, B.B.: A simple, sensitive method for the assay of adenylyl cyclase, J. Pharmacol. Exp. Ther. 163:379-385, 1968.
17. Weiss, B. and Costa, E.: Regional and subcellular distribution of adenylyl cyclase and 3',5'-cyclic nucleotide phosphodiesterase in brain and pineal gland. Biochem. Pharmacol. 17:2107-2116, 1968.
18. Weiss, B.: Similarities and differences in the norepinephrine and sodium fluoride-sensitive adenylyl cyclase system. J. Pharmacol. Exp. Ther. 166:330-338, 1969.
19. Weiss, B.: Effects of environmental lighting and chronic denervation on the activation of adenylyl cyclase of rat pineal gland by norepinephrine and sodium fluoride. J. Pharmacol. Exp. Ther. 168:146-152, 1969.
20. Weiss, B. and Kidman, A.D.: Neurobiological significance of cyclic 3',5'-adenosine monophosphate. In: Advances in Biochemical Psychopharmacology, Vol. 1, eds. E. Costa and P. Greengard, Raven Press, New York, pp. 131-164, 1969.
21. Weiss, B.: Factors affecting adenylyl cyclase activity and its sensitivity to biogenic amines. In: Society of General Physiologists Symposium on Biogenic Amines as Physiological Regulators. ed. J.J. Blum, Prentice Hall, New Jersey pp. 35-73, 1970.
22. Weiss, B. and Crayton, J.: Gonadal hormones as regulators of pineal adenylyl cyclase activity. Endocrinology 87:527-533, 1970.
23. Weiss, B. and Crayton, J.: Neural and hormonal regulation of pineal adenylyl cyclase activity. In: Role of Cyclic AMP in Cell Function: Advances in Biochemical Psychopharmacology, Vol. 3 eds. E. Costa and P. Greengard, Raven Press, New York, pp. 217-239, 1970.
24. Ebadi, M.S., Weiss, B. and Costa, E.: Adenosine 3',5'-monophosphate in rat pineal gland: increase induced by light. Science 170:188-190, 1970.
25. Ebadi, M.S., Weiss, B. and Costa, E.: Regional distribution of cyclic 3',5'-AMP in rat brain. Trans. Am. Neuro. Assoc. 95:125-128, 1970.
26. Ebadi, M.S., Weiss, B. and Costa, E.: Microassay of adenosine 3',5'-monophosphate (cyclic AMP) in brain and other tissues by the luciferin-luciferase system. J. Neurochem. 18:183-192, 1971.
27. Weiss, B.: Ontogenetic development of adenylyl cyclase and phosphodiesterase in rat brain. J. Neurochem. 18:469-477, 1971.
28. Kidman, A.D., Weiss, B. and Costa, E.: Protein metabolism and amino acid accumulation in the

- rat submaxillary gland during reduced sympathetic activity. J. Neurochem. 18:817-826, 1971.
29. Ebadi, M.S., Weiss, B. and Costa, E.: Distribution of cyclic adenosine monophosphate in rat brain. Arch. Neurol. 24:353-357, 1971.
 30. Weiss, B.: On the regulation of adenylyl cyclase activity in the rat pineal gland. In: Cyclic AMP and Cell Function, eds. G.A. Robison, G.G. Nahas and L. Triner. N.Y. Acad. Sci. 185:507-519, 1971.
 31. Uzunov, P. and Weiss, B.: Effects of phenothiazine tranquilizers on the cyclic 3',5'-adenosine monophosphate system of rat brain. Neuropharmacology 10:697-708, 1971.
 32. Weiss, B., Shein, H.M. and Snyder, R.L.: Adenylyl cyclase and phosphodiesterase activity of normal and SV₄₀ virus-transformed hamster astrocytes in cell culture. Life Sci. 10:1253-1260, 1971.
 33. Weiss, B., Lehne, R. and Strada, S.: Rapid microassay of adenosine 3',5'-monophosphate phosphodiesterase activity. Anal. Biochem. 45:222-235, 1972.
 34. Strada, S.J., Klein, D.C., Weller, J. and Weiss, B.: Effect of norepinephrine on the concentration of adenosine 3',5'-monophosphate of rat pineal gland in organ culture. Endocrinology 90:1470-1475, 1972.
 35. Uzunov, P. and Weiss, B.: Separation of multiple molecular forms of cyclic adenosine 3',5'-monophosphate phosphodiesterase in rat cerebellum by polyacrylamide gel electrophoresis. Biochim. Biophys. Acta 284:220-226, 1972.
 36. Guidotti, A., Weiss, B. and Costa, E.: Adenosine 3',5'-monophosphate concentrations and isoproterenol-induced synthesis of deoxyribonucleic acid in mouse parotid gland. Mol. Pharmacol. 8:521-530, 1972.
 37. Weiss, B. and Strada, S.J.: Neuroendocrine control of the cyclic AMP system of brain and pineal gland. Adv. Cycl. Nucl. Res. 1:357-374, 1972.
 38. Uzunov, P. and Weiss, B.: Psychopharmacological agents and the cyclic adenosine 3',5'-monophosphate system of rat brain. Adv. Cycl. Nucl. Res. 1:435-453, 1972.
 39. Weiss, B. and Strada, S.J.: Adenosine 3',5'-monophosphate during fetal and postnatal development. In: Fetal Pharmacology, L. Boreus, Raven Press, New York, pp. 205-235, 1973.
 40. Uzunov, P., Shein, H.M. and Weiss, B.: Cyclic AMP phosphodiesterase in cloned astrocytoma cells: norepinephrine induces a specific enzyme form. Science 180:304-306, 1973.
 41. Weiss, B.: Selective regulation of the multiple forms of cyclic nucleotide phosphodiesterase by norepinephrine and other agents. In: Frontiers in Catecholamine Research, eds. E. Usdin and S. Snyder, Pergamon Press, New York, pp. 327-333, 1973.

42. Weiss, B.: Regulation of the multiple forms of cyclic nucleotide phosphodiesterase. Life Sci. 13:R167-R169, 1973.
43. Strada, S.J. and Weiss, B.: Increased response to catecholamines of the cyclic AMP system of rat pineal gland induced by decreased sympathetic activity. Arch. Biochem. Biophys. 160:197-204, 1974.
44. Fertel, R. and Weiss, B.: A microassay for guanosine 3',5'-monophosphate phosphodiesterase activity. Anal. Biochem. 59:386-398, 1974.
45. Uzunov, P., Shein, H.M. and Weiss, B.: Multiple forms of cyclic 3',5'-AMP phosphodiesterase of rat cerebrum and cloned astrocytoma and neuroblastoma cells. Neuropharmacology 13:377-391, 1974.
46. Weiss, B., Fertel, R., Figlin, R. and Uzunov, P.: Selective alteration of the activity of the multiple forms of adenosine 3',5'-monophosphate phosphodiesterase of rat cerebrum. Mol. Pharmacol. 10:615-625, 1974.
47. Strada, S.J., Uzunov, P. and Weiss, B.: Ontogenetic development of a phosphodiesterase activator and the multiple forms of cyclic AMP phosphodiesterase of rat brain. J. Neurochem. 23:1097-1103, 1974.
48. Weiss, B.: Differential activation and inhibition of the multiple forms of cyclic nucleotide phosphodiesterase. Adv. Cycl. Nucl. Res. 5:195-211, 1975.
49. Weiss, B. (ed.): Cyclic Nucleotides in Disease, University Park Press, Baltimore, Md., 1975.
50. Weiss, B. and Greenberg, L.H.: Cyclic AMP and brain function: Effects of psychopharmacologic agents on the cyclic AMP system. In: Cyclic Nucleotides in Disease, ed. B. Weiss, University Park Press, Baltimore, pp. 269-320, 1975.
51. Hait, W.N. and Weiss, B.: Increased cyclic nucleotide phosphodiesterase activity in leukemic lymphocytes. Nature 259:321-323, 1976.
52. Fertel, R. and Weiss, B.: Properties and drug responsiveness of cyclic nucleotide phosphodiesterases of rat lung. Mol. Pharmacol. 12:678-687, 1976.
53. Levin, R.M. and Weiss, B.: Mechanism by which psychotropic drugs inhibit adenosine cyclic 3',5'-monophosphate phosphodiesterase of brain. Mol. Pharmacol. 12:581-589, 1976.
54. Weiss, B. and Fertel, R.: Pharmacologic control of the synthesis and metabolism of cyclic nucleotides. Adv. Pharmacol. Chemotherp. 14:189-283, 1977.
55. Weiss, B. and Hait, W.N.: Selective cyclic nucleotide phosphodiesterase inhibitors as potential therapeutic agents. Ann. Rev. Pharmacol. Toxicol. 17:441-477, 1977.

56. Levin, R.M. and Weiss, B.: Binding of trifluoperazine to the calcium-dependent activator of cyclic nucleotide phosphodiesterase. Mol. Pharmacol. 13:690-697, 1977.
57. Hait, W.N. and Weiss, B.: Characteristics of the cyclic nucleotide phosphodiesterases of normal and leukemic lymphocytes. Biochim. Biophys. Acta 497:86-100, 1977.
58. Greenberg, L.H., Dix, R.K. and Weiss, B.: Age-related changes in the binding of ³H-dihydroalprenolol in rat brain. In: Pharmacological Intervention in the Aging Process, eds. J. Roberts, R.C. Adelman and V.J. Cristofalo, Plenum Press, New York, pp. 245-249, 1978.
59. Levin, R.M. and Weiss, B.: Characteristics of the cyclic nucleotide phosphodiesterases in a transplantable pheochromocytoma and adrenal medulla of the rat. Cancer Res. 38:915-920, 1978.
60. Levin, R.M. and Weiss, B.: Specificity of the binding of trifluoperazine to the calcium-dependent activator of phosphodiesterase and to a series of other calcium-binding proteins. Biochim. Biophys. Acta 540:197-204, 1978.
61. Weiss, B. and Levin, R.M.: Mechanism for selectively inhibiting the activation of cyclic nucleotide phosphodiesterase and adenylate cyclase by antipsychotic agents. Adv. Cycl. Nucl. Res. 9:285-304, 1978.
62. Weiss, B. and Greenberg, L.H.: Physiological and pharmacological significance of the multiple forms of the cyclic nucleotide phosphodiesterase. In: Molecular Biology and Pharmacology of Cyclic Nucleotides, eds. E. Folco and R. Paoletti, Elsevier/North Holland Biomedical Press, pp. 69-84, 1978.
63. Fertel, R. and Weiss, B.: Measurement of the activity of cyclic nucleotide phosphodiesterases with firefly luciferin-luciferase coupled assay systems. In: Methods in Enzymology, eds. S.P. Colowick and N.O. Kaplan, Academic Press, New York, 57:94-106, 1978.
64. Weiss, B. and Winchurch, R.A.: Analyses of cyclic nucleotide phosphodiesterases in lymphocytes from normal and aged leukemic mice. Cancer Res. 38:1274-1280, 1978.
65. Greenberg, L.H., Troyer, E., Ferrendelli, J.A. and Weiss, B.: Enzymatic regulation of the concentration of cyclic GMP in mouse brain. Neuropharmacology 17:737-745, 1978.
66. Glaubiger, G., Tsai, B.S., Lefkowitz, R.J., Johnson, E.M., Jr. and Weiss, B.: Chronic guanethidine treatment increases cardiac beta-adrenergic receptors. Nature 273:240-242, 1978.
67. Greenberg, L.H. and Weiss, B.: Beta adrenergic receptors in aged rat brain: reduced number and capacity of pineal gland to develop supersensitivity. Science 201:61-63, 1978.
68. Greenberg, L.H. and Weiss, B.: Beta-adrenergic receptors in aging rat brain: modifications induced by psychotropic drugs. In: Recent Advances in Pharmacology of Adrenoceptors, eds. E. Szabadi, C.M. Bradshaw and P. Bevan, Elsevier/North Holland Biomedical Press, pp. 241-250, 1978.

69. Winchurch, R., Hait, W. and Weiss, B.: Cyclic AMP phosphodiesterase activity of murine T and B lymphocytes. Cell. Immunol. 41:421-426, 1978.
70. Levin, R.M. and Weiss, B.: Selective binding of antipsychotics and other psychoactive agents to the calcium-dependent activator of cyclic nucleotide phosphodiesterase. J. Pharmacol. Exp. Ther. 208:454-459, 1979.
71. Weiss, B., Greenberg, L. and Cantor, E.: Age-related alterations in the development of adrenergic denervation supersensitivity. Fed. Proc. 38:1915-1921, 1979.
72. Weiss, B., Levin, R.M. and Greenberg, L.H.: Modulation of cyclic nucleotide metabolism by antipsychotics through a non-dopamine receptor. In: Catecholamines: Basic and Clinical Frontiers, eds. E. Usdin, I.J. Kopin and J. Barchas, Pergamon Press, N.Y. pp. 529-531, 1979.
73. Hait, W.N. and Weiss, B.: Cyclic nucleotide phosphodiesterase of normal and leukemic lymphocytes: kinetic properties and selective alteration of the activity of the multiple molecular forms. Mol. Pharmacol. 16:851-864, 1979.
74. Moyer, J.A., Greenberg, L.H., Frazer, A., Brunswick, D.J., Mendels, J. and Weiss, B.: Opposite effects of acute and repeated administration of desmethylimipramine on adrenergic responsiveness in rat pineal gland. Life Sci. 24:2237-2244, 1979.
75. Greenberg, L.H. and Weiss, B.: Ability of aged rats to alter beta-adrenergic receptors of brain in response to repeated administration of reserpine and desmethylimipramine. J. Pharmacol. Exp. Ther. 211:309-316, 1979.
76. Levin, R.M. and Weiss, B.: Inhibition by trifluoperazine of calmodulin-induced activation of ATPase activity of rat erythrocytes. Neuropharmacology 19:169-174, 1980.
77. Weiss, B. and Greenberg, L.H.: Modulation of beta-adrenergic receptors and calmodulin following acute and chronic treatment with neuroleptics. In: Adv. Biochem. Psychopharmacol., Vol. 24 - Long-Term Effects of Neuroleptics, eds. F. Cattabeni, G. Racagni, P.F. Spano and E. Costa, Raven Press, New York, pp. 139-146, 1980.
78. Weiss, B., Greenberg, L.H. and Cantor, E.: Denervation supersensitivity and beta-adrenergic receptors as a function of age. In: Receptors for Neurotransmitters and Peptide Hormones, eds. G. Pepeu, M.J. Kuhar and S.J. Enna, Raven Press, New York, p 461-472, 1980.
79. Weiss, B., Prozialeck, W. and Cimino, M.: Acute and chronic effects of psychoactive drugs on adrenergic receptors and calmodulin. Adv. Cycl. Nucl. Res. 12:213-225, 1980.
80. Weiss, B. and Wallace, T.L.: Mechanisms and pharmacological implications of altering calmodulin activity. In: Calcium and Cell Function, Vol. 1, ed. W.Y. Cheung, Academic Press, New York, pp. 329-379, 1980.

81. Weiss, B., Prozialeck, W., Cimino, M., Barnette, M.S. and Wallace, T.L.: Pharmacological regulation of calmodulin. In: Calmodulin and Cell Functions, Ann. N.Y. Acad. Sci. 356:319-345, 1980.
82. Cantor, E.H., Greenberg, L.H. and Weiss, B.: Effect of long term changes in sympathetic nervous activity on the beta-adrenergic receptor adenylate cyclase complex of rat pineal gland. Mol. Pharmacol. 19:21-26, 1981.
83. Prozialeck, W.C., Cimino, M. and Weiss, B.: Photoaffinity labeling of calmodulin by phenothiazine antipsychotics. Mol. Pharmacol. 19:264-269, 1981.
84. Moyer, J.A., Greenberg, L.H., Frazer, A. and Weiss, B.: Subsensitivity of the beta-adrenergic receptor-linked adenylate cyclase system of rat pineal gland following repeated treatment with desmethylimipramine and nialamide. Mol. Pharmacol. 19:187-193, 1981.
85. Weiss, B. and Sellinger-Barnette, M.: Effects of antipsychotic dopamine antagonists and polypeptide hormones on calmodulin. In: Apomorphine and Other Dopaminomimetics, Vol. 1 - Basic Pharmacology, eds. G.L. Gessa and G.U. Corsini, Raven Press, New York, pp. 179-192, 1981.
86. Heydorn, W.E., Frazer, A. and Weiss, B.: Electrical stimulation of sympathetic nerves increases the concentration of cyclic AMP in rat pineal gland. Proc. Natl. Acad. Sci. U.S.A. 78:7176-7179, 1981.
87. Cantor, E., Clark, M.B., and Weiss, B.: Effect of sympathetic input on ontogeny of beta-adrenergic receptors in rat pineal gland. Brain Res. Bull. 7:243-247, 1981.
88. Weiss, B., Heydorn, W. and Frazer, A.: Modulation of the beta-adrenergic receptor-adenylate cyclase system following acute and repeated treatment with antidepressants. In: Typical and Atypical Antidepressants: Molecular Mechanisms, Vol. 31, Adv. Biochem. Psychopharmacol., eds. E. Costa and G. Racagni, Raven Press, New York, pp. 37-53, 1982.
89. Sellinger-Barnette, M. and Weiss, B.: Interaction of beta-endorphin and other opioid peptides with calmodulin. Mol. Pharmacol. 21:86-91, 1982.
90. Weiss, B., Prozialeck, W.C. and Wallace, T.L.: Interaction of drugs with calmodulin: Biochemical, pharmacological and clinical implications. Biochem. Pharmacol. 31:2217-2226, 1982.
91. Prozialeck, W.C. and Weiss, B.: Inhibition of calmodulin by phenothiazines and related drugs; structure-activity relationships. J. Pharmacol. Exptl. Therap. 222:509-516, 1982.
92. Greenberg, L.H. and Weiss, B.: Neuroendocrine control of catecholaminergic receptors in aging brain. In: Aging, Vol 23: Aging Brain and Ergot Alkaloids, eds., A. Agnoli, G. Crepaldi, P.F. Spano and M. Trabucchi, Raven Press, New York, pp. 37-52, 1983.

93. Weiss, B.: Techniques for measuring the interaction of drugs with calmodulin. In: Methods in Enzymology, eds. A.R. Means and B.W. O'Malley, Academic Press, New York, 102:171-184, 1983.
94. Freilich, J. and Weiss, B.: Altered adaptive capacity of brain catecholaminergic receptors during aging. In: The Aging of the Brain, eds. D. Samuel, S. Algeri, S. Gershon, V.E. Grimm and G. Toffano, Raven Press, New York, 22:277-300, 1983.
95. Barnette, M.S., Daly, R. and Weiss, B.: Inhibition of calmodulin activity by insect venom peptides. Biochem. Pharmacol., 32:2929-2933, 1983.
96. Weiss, B., Earl, C. and Prozialeck, W.C.: Biochemical and possible neuropsychopharmacological implications of inhibiting calmodulin activity. Psychopharmacol. Bull., 19:378-386, 1983.
97. Barnette, M.S. and Weiss, B.: Interaction of neuropeptides with calmodulin. A structure-activity study. Psychopharmacol. Bull., 19:387-392, 1983.
98. Weiss, B., Clark, M.B. and Greenberg, L.H.: Modulation of catecholaminergic receptors during development and aging. In: Handbook of Neurochemistry, ed. A. Lajtha, Plenum Press, New York, Vol. 6, pp. 595-627, 1984.
99. Weiss, B., Greenberg, L.H. and Clark, M.B.: Physiological and pharmacological modulation of the beta-adrenergic receptor-linked adenylate cyclase system: supersensitivity and subsensitivity. In: Dynamics of Neurotransmitter Function, ed. I. Hanin, Raven Press, New York, pp. 319-330, 1984.
100. Sellinger-Barnette, M.S. and Weiss, B.: Interaction of various peptides with calmodulin. Adv. Cycl. Nucl. Res., eds. S.J. Strada and W.J. Thompson, Vol. 16, pp. 261-276, 1984.
101. Greenberg, L.H. and Weiss, B.: Neural and hormonal modulation of adrenergic receptors in aging. In: Altered Endocrine Status During Aging, ed. Cristofalo, V. and Roberts, J., Alan R. Liss, Inc., New York, pp. 57-70, 1984.
102. Earl, C.Q., Prozialeck, W.C. and Weiss, B.: Interaction of alpha adrenergic antagonists with calmodulin. Life Sci. 35:525-534, 1984.
103. Weiss, B. and Prozialeck, W.C.: Pharmacological inhibition of calmodulin-dependent processes. In: Mechanisms of Hepatic Injury and Death, ed. D. Keppler, H. Popper, L. Bianchi and W. Reutter, MTP Press, Lancaster, England pp. 337-352, 1984.
104. Zhou, L.W., Weiss, B., Freilich, J.S. and Greenberg, L.H.: Impaired recovery of alpha₁ and alpha₂-adrenergic receptors in brain tissue of aged rats. J. Gerontol. 39:538-546, 1984.
105. Prozialeck, W.C. and Weiss, B.: Mechanisms of pharmacologically altering calmodulin activity. In: Calcium in Biological Systems, ed. G. Weiss, J. Putney and R. Rubin, Plenum Press, New York, pp. 255-264, 1985.

106. Greenberg, L.H., Brunswick, D.J. and Weiss, B.: Effect of age on the rate of recovery of beta-adrenergic receptors in rat brain following desmethylimipramine-induced subsensitivity. Brain Res. 328:81-88, 1985.
107. Weiss, B., Sellinger-Barnette, M., Winkler, J.D., Schechter, L. and Prozialeck, W.C.: Calmodulin antagonists: structure-activity relationships. In: Calmodulin Antagonists and Cellular Physiology, ed. H. Hidaka and D.J. Hartshorne, Academic Press, New York, pp. 45-61, 1985.
108. Zhou, L-W., Moyer, J.A., Muth, E.A., Clark, B., Palkovits, M. and Weiss, B.: Regional distribution of calmodulin activity in rat brain. J. Neurochem. 44:1657-1662, 1985.
109. Barnette, M.S. and Weiss, B.: Inhibition of calmodulin-stimulated phosphodiesterase activity by vasoactive intestinal peptide. J. Neurochem., 45:640-643, 1985.
110. Thermos, K. and Weiss, B.: Calmodulin: Function and pharmacological regulation. In: Spasmophilia: Calcium Metabolism and Cell Physiology, ed. A. Agnoli, P.L. Canonico, G. Milhaud and U. Scapagnini. John Libby & Co., London pp.26-37,1985.
111. Weiss, B., Goodale, D.B., Seyfried, D.M., Thermos, K. and Winkler, J.D., Modulation of dopaminergic behavioral responses. In: Symposia in Neuroscience, Vol. 3: Modulation of Central and Peripheral Transmitter Function, ed. G. Biggio, P.F. Spano, G. Toffano and G.L. Gessa, Liviana Press, Padova, Italy pp. 105-116, 1986.
112. Winkler, J.D. and Weiss, B.: Reversal of supersensitive apomorphine-induced rotational behavior in mice by continuous exposure to apomorphine. J. Pharmacol. Exptl. Therap., 238:242-247, 1986.
113. Winkler, J.D., Thermos, K. and Weiss, B.: Differential effects of fluphenazine-N-mustard on calmodulin activity and on D₁ and D₂ dopaminergic responses. Psychopharmacology, 92:285-291, 1987.
114. Prozialeck, W.C., Wallace, T.L. and Weiss, B.: Differential inhibition of calmodulin-sensitive phosphodiesterase and Ca⁺⁺ adenosine triphosphatase by chlorpromazine-linked calmodulin. J. Pharmacol. Exptl. Therap., 243:171-179, 1987.
115. Thermos, K., Winkler, J.D. and Weiss, B.: Comparison of the effects of fluphenazine-N-mustard on dopamine binding sites and on behavior induced by apomorphine in supersensitive mice. Neuropharmacology, 26:1473-1480, 1987.
116. Winkler, J.D., Callison, K., Cass, S. and Weiss, B.: Selective down-regulation of D₁ dopamine mediated rotational behavior in supersensitive mice. Neuropharmacology, 27:439-442, 1988.
117. Goodale, D.B., Jacobi, A.G.M., Seyfried, D.M. and Weiss, B.: Selective protection from the inhibition by EEDQ of D₁ and D₂ dopamine agonist induced rotational behavior in mice. Pharmacol. Biochem. Behav., 40:457-462, 1988.

118. Cimino, M. and Weiss, B.: Characteristics of the binding of phenoxybenzamine to calmodulin. Biochem. Pharmacol., 37:2739-2745, 1988.
119. Weiss, B.: Modulation of adrenergic receptors during aging. Neurobiol. Aging, 9:61-62, 1988.
120. Weiss, B., Prozialeck, W.C. and Roberts-Lewis, J.M.: Development of selective inhibitors of calmodulin-dependent phosphodiesterase and adenylate cyclase; in Design of Enzyme Inhibitors as Drugs, ed. M. Sandler and H.J. Smith, Oxford University Press, New York, pp. 650-697, 1989.
121. Weiss, B., Cimino, M., Winkler, J.D. and Chen, J.F.: Behavioral, biochemical and molecular biological correlates of modulating dopaminergic responses. Neurochemical Pharmacology, - A Tribute to B. B. Brodie., ed. E. Costa, Raven Press, New York, pp 151-166, 1989.
122. Winkler, J.D. and Weiss, B.: Effect of continuous exposure to selective D₁ and D₂ dopaminergic agonists on rotational behavior in supersensitive mice. J. Pharmacol. Exptl. Therap., 249:507-516, 1989.
123. Cimino, M., Cattabeni, F. and Weiss, B.: In situ hybridization histochemistry as a tool to study gene expression and its regulation in the central nervous system. Pharmacol. Res., 21:67-77, 1989.
124. Roberts-Lewis, J.M., Cimino, M., Krause, R.G., Tyrrell, D.F., Davis, L.G., Weiss, B. and Lewis, M.E.: Anatomical localization of calmodulin mRNA in the rat brain with cloned cDNA and synthetic oligonucleotide probes. Synapse 5:247-254, 1990.
125. Cimino, M., Chen, J.F. and Weiss, B.: Ontogenetic development of calmodulin mRNA in rat brain using in situ hybridization histochemistry. Develop. Brain Res. 54:43-49, 1990.
126. Weiss, B., Zhou, L.-W., Chen, J.F., Szele, F. and Bai, G.: Distribution and modulation of the D₂ dopamine receptor mRNA in mouse brain: molecular and behavioral correlates. Adv. Biosci., 77:9-25, 1990.
127. Zhang, S., Prozialeck, W. and Weiss, B.: Differential inhibition of calcium-dependent and calmodulin-dependent enzymes by drug calmodulin adducts. Mol. Pharmacol., 38: 698-704, 1990.
128. Chen, J.F., Qin, Z.-H., Szele, F., Bai, G. and Weiss, B.: Neuronal localization and modulation of the D₂ dopamine receptor mRNA in brain of normal mice and mice lesioned with 6-hydroxydopamine. Neuropharmacology, 30:927-941, 1991.
129. Zhou, L.-W., Qin, Z.-H. and Weiss, B.: Downregulation of stereotyped behavior and production of latent locomotor behaviors in mice treated continuously with quinpirole. Neuropsychopharmacology, 4:47-55, 1991.
130. Cimino, M., Zoli, M. and Weiss, B.: Differential ontogenetic expression and regulation of proenkephalin and preprosomatostatin mRNAs in rat caudate-putamen as studied by in situ hybridization histochemistry. Develop. Brain Res., 60: 115-122, 1991.

131. Chen, J.F. and Weiss, B.: Ontogenetic expression of D₂ dopamine receptor mRNA in rat corpus striatum. Develop. Brain Res., 63: 95-104, 1991.
132. Bai, G. and Weiss, B.: The increase of calmodulin in PC12 cells induced by NGF is caused by differential expression of multiple mRNAs for calmodulin. J. Cell Physiol. 149:414-421, 1991.
133. Weiss, B., Chen, J.F, Zhang, S. and Zhou, L.-W.: Developmental and age-related changes in the D₂ dopamine receptor mRNA subtypes in rat brain. Neurochem. Internat., 20:49S-58S, 1992.
134. Bai, G., Nichols, R.A. and Weiss, B.: Cyclic AMP selectively up-regulates calmodulin genes I and II in PC12 cells. Biochim. Biophys. Acta., 1130:189-196, 1992.
135. Zhou, L.-W., Zhang, S.-P., Welsh, S., Connell, T.A. and Weiss, B.: Triazolam blocks the initial rotational effects of quinpirole but permits the later developing reduction of dopamine D₂-mediated rotational behavior and dopamine D₂ receptors. Eur. J. Pharmacol., 218:219-227, 1992.
136. Zhou, L.-W., Zhang, S.-P., Connell, T.A. and Weiss, B.: Cholinergic lesions of mouse striatum induced by AF64A alter dopaminergic behavior and reduce D₂ dopamine receptors and D₂ dopamine receptor mRNA. Neurochem. Internat., 22:301-311, 1993.
137. Wang, H.-Y., Zhou, L.-W., Friedman, E. and Weiss, B.: Differential regulation of release of acetylcholine in the striatum in mice following continuous exposure to selective D1 and D₂ dopaminergic agonists. Neuropharmacology, 32:85-91, 1993.
138. Zhang, S.-P., Zhou, L.-W., Natsukari, N. and Weiss, B.: Continuously infusing quinpirole decreases Ca²⁺/calmodulin-dependent phosphorylation in mouse striatum. Neurochem. Internat., 23:361-372, 1993.
139. Chen, J.F., Aloyo, V.J. and Weiss, B.: Continuous treatment with the D₂ dopamine receptor agonist quinpirole decreases D₂ dopamine receptors, D₂ dopamine receptor messenger RNA and proenkephalin messenger RNA, and increases mu opioid receptors in mouse striatum. Neuroscience, 54:669-680, 1993.
140. Zhou, L.-W., Zhang, S.-P., Connell, T.A. and Weiss, B.: AF64A lesions of mouse striatum result in ipsilateral rotations to D₂ dopamine agonists but contralateral rotations to muscarinic cholinergic agonists. J. Pharmacol. Exptl. Therap., 264:824-830, 1993.
141. Zhang, S.-P., Natsukari, N., Bai, G., Nichols, R.A. and Weiss, B.: Localization of the multiple calmodulin messenger RNAs in differentiated PC12 cells. Neuroscience, 55:571-582, 1993.
142. Chen, J.F. and Weiss, B.: Irreversible blockade of D₂ dopamine receptors by fluphenazine-N-mustard increases glutamic acid decarboxylase mRNA in rat striatum. Neurosci. Lett., 150:215-218, 1993.
143. Weiss, B., Zhou, L.-W., Zhang, S.-P. and Qin, Z.-H.: Antisense oligodeoxynucleotide inhibits D₂ dopamine receptor-mediated behavior and D₂ messenger RNA. Neuroscience, 55:607-612, 1993.

144. Qin, Z.-H., Zhang, S.-P. and Weiss, B.: Dopaminergic and glutamatergic blocking drugs differentially regulate glutamic acid decarboxylase mRNA in mouse brain. Mol. Brain Res., 21:293-302, 1994.
145. Zhang, S.-P., Zhou, L.-W. and Weiss, B.: Oligodeoxynucleotide antisense to the D₁ dopamine receptor mRNA inhibits D₁ dopamine receptor-mediated behaviors in normal mice and in mice lesioned with 6-hydroxydopamine. J. Pharmacol. Exptl. Therap., 271:1462-1470, 1994.
146. Qin, Z.-H., Chen, J.F. and Weiss, B.: Lesions of mouse striatum induced by 6-hydroxydopamine differentially alter the density, rate of synthesis and level of gene expression of D₁ and D₂ dopamine receptors. J. Neurochem., 62:411-420, 1994.
147. Zhou, L.-W., Zhang, S.-P., Qin, Z.-H. and Weiss, B.: In vivo administration of an oligodeoxynucleotide antisense to the D₂ dopamine receptor mRNA inhibits D₂ dopamine receptor-mediated behavior and the expression of D₂ dopamine receptors in mouse striatum. J. Pharmacol. Exptl. Therap., 268:1015-1023, 1994.
148. Qin, Z.-H., Zhou, L.-W. and Weiss, B.: D₂ dopamine receptor messenger RNA is altered to a greater extent by blockade of glutamate receptors than by blockade of dopamine receptors. Neuroscience, 60:97-114, 1994.
149. Chen, J.-F., Aloyo, V.A., Qin, Z.-H. and Weiss, B.: Irreversible blockade of D₂ dopamine receptors by fluphenazine-N-mustard increases D₂ dopamine receptor mRNA and proenkephalin mRNA and decreases D₁ dopamine receptor mRNA and mu and delta opioid receptors in rat striatum. Neurochem. Internat., 25:355-366, 1994.
150. Qin, Z.-H. and Weiss, B.: Dopamine receptor blockade increases dopamine D₂ receptor and glutamic acid decarboxylase mRNAs in mouse substantia nigra. Eur. J. Pharmacol., 269:25-33, 1994.
151. Natsukari, N., Zhang, S.-P., Nichols, R. and Weiss, B.: Immunocytochemical localization of calmodulin in PC12 cells and its possible interaction with histones. Neurochem. Internat., 26:465-476, 1995.
152. Zhang, S.-P., Connell, T.A., Price, T., Simpson, G.M., Zhou, L.-W., Weiss, B.: Continuous infusion of clozapine increases mu and delta opioid receptors and proenkephalin mRNA in mouse brain. Biol. Psychiat., 37:496-503, 1995.
153. Qin, Z.-H., Zhou, L.-W., Zhang, S.-P., Wang, Y. and Weiss, B.: D₂ dopamine receptor antisense oligodeoxynucleotide inhibits the synthesis of a functional pool of D₂ dopamine receptors. Mol. Pharmacol., 48:730-737, 1995.
154. Weiss, B., Zhou, L.-W. and Zhang, S.-P.: Dopamine antisense oligodeoxynucleotides as potential novel tools for studying drug abuse. In: Antisense Strategies for the Study of Receptor Mechanisms, eds. R.B. Raffa and F. Porreca, R.G. Landes Publ. Co., Georgetown, TX, pp. 71-91, 1996.

155. Zhou, L.-W., Zhang, S.-P. and Weiss, B.: Intrastriatal administration of an oligodeoxynucleotide antisense to the D₂ dopamine receptor mRNA inhibits D₂ dopamine receptor-mediated behavior and D₂ dopamine receptors in normal mice and in mice lesioned with 6-hydroxydopamine. Neurochem. Internat., 29:583-595, 1996.
156. Weiss, B., Zhou, L.-W. and Davidkova, G.: Pharmacological and molecular regulation of the expression of dopamine receptors. In: Pharmacological Regulation of Gene Expression in the Central Nervous System, ed. K.M. Merchant, CRC Press, Boca Raton, FL, pp. 175-196, 1996.
157. Davidkova, G., Zhang, S.-P., Nichols, R.A. and Weiss, B.: Reduced level of calmodulin in PC12 cells induced by stable expression of calmodulin antisense RNA inhibits cell growth and induces neurite outgrowth. Neuroscience, 75:1003-1019, 1996.
158. Zhang, S.-P., Zhou, L.-W., Morabito, M., Lin, R.C.S. and Weiss, B.: Uptake and distribution of fluorescein-labeled D₂ dopamine receptor antisense oligodeoxynucleotide in mouse brain. J. Mol. Neurosci., 7:13-28, 1996.
159. Weiss, B.: Antisense oligodeoxynucleotides and antisense RNA expression vectors reveal a functional pool of neurotransmitter receptors. In: Antisense Strategies in the Neurosciences, INSERM, Atelier 83, Le Vesinet, 1996.
160. Hadjiconstantinou, M., Neff, N.H., Zhou, L.-W., and Weiss, B.: D₂ dopamine receptor antisense increases the activity and mRNA of tyrosine hydroxylase and aromatic L-amino acid decarboxylase in mouse brain. Neurosci. Lett., 217:105-108, 1996.
161. Weiss, B., Zhang, S.-P. and Zhou, L.-W.: Antisense strategies in dopamine receptor pharmacology. Life Sci., 60:433-455, 1997.
162. Weiss, B., Davidkova, G. and Zhang, S.-P.: Antisense strategies in neurobiology. Neurochem. Internat., 31:321-348, 1997.
163. Davidkova, G., Zhang, S.-P., Zhou, L.-W., Nichols, R.A. and Weiss, B.: Use of plasmid antisense RNA expression vectors in neurobiology. In: "Antisense Oligodeoxynucleotides and Antisense RNA: Novel Pharmacological and Therapeutic Agents", ed., B. Weiss, CRC Press, Boca Raton, FL, pp. 213-241, 1997.
164. Weiss, B. (ed.): Antisense Oligodeoxynucleotides and Antisense RNA : Novel Pharmacological and Therapeutic Agents, CRC Press, Boca Raton, FL, 1997.
165. Weiss, B., Davidkova, G., Zhou, L.-W., Zhang, S.-P. and Morabito, M.: Expression of a D₂ dopamine receptor antisense RNA in brain inhibits D₂-mediated behaviors. Neurochem. Internat., 31:571-580, 1997.
166. Hou, W.-F., Zhang, S.-P., Davidkova, G., Nichols, R.A. and Weiss, B.: Effect of antisense oligodeoxynucleotides directed to individual calmodulin gene transcripts on the proliferation and differentiation of PC12 cells. Antisense Nucleic Acid Drug Develop., 8: 295-308, 1998.

167. Davidkova, G., Zhang, S.-P., Zhou, L.-W., and Weiss, B.: Effects of dopamine receptor antisense RNA expression vectors in the nervous system, In: Modulating Gene Expression by Antisense Oligonucleotides to Understand Neural Functioning. McCarthy, M. M. (Ed.) Kluwer Academic Publishers, Norwell, Mass., pp.61-82 , 1998.
168. Davidkova, G. and Weiss, B.: Pharmacological inhibition of dopaminergic and other neurotransmitter receptors using antisense oligodeoxynucleotides. In: Handbook of Experimental Pharmacology: Antisense Research and Application, ed., S. Crooke, Springer-Verlag, Berlin, Germany. 131:263-308, 1998.
169. Davidkova, G., Zhou, L.-W., Morabito, M., Zhang, S.-P., and Weiss, B.: D2 dopamine antisense RNA expression vector, unlike haloperidol, produces long-term inhibition of D2 dopamine-mediated behaviors without causing upregulation of D2 dopamine receptors. J. Pharmacol. Exptl. Therap., 285:1187-1196, 1998.
170. Weiss, B. and Davidkova, G.: Cyclic Nucleotides. In: Encyclopedia of Neuroscience, eds. G. Adelman and B.H. Smith, Elsevier Science Publ., Amsterdam, pp. 503-506, 1999.
171. Weiss, B., Davidkova, G., and Zhou, L.-W.: Antisense RNA gene therapy for studying and modulating biological processes. Cell. Mol. Life Sci. , 55:334-358, 1999.

ABSTRACTS

1. Weiss, B.: Metabolism of dopa-C¹⁴ in the normal and alpha-methyldopa treated mouse. Fed. Proc. 22:540, 1963.
2. Weiss, B. and Maickel, R.P.: Pharmacological demonstration of sympathetic innervation of adipose tissue. Pharmacologist 6:172, 1964.
3. Maickel, R.P., Davies, J.I. and Weiss, B.: Cyclic 3',5'-AMP: An intermediate in the activation of adipose tissue lipolytic activity. Fed. Proc. 24:299, 1965.
4. Krishna, G., Weiss, B., Davies, J.I. and Hynie, S.: Mechanism of nicotinic acid inhibition of hormone-induced lipolysis. Fed. Proc. 25:719, 1966.
5. Weiss, B. and Costa, E.: Effects of denervation and environmental lighting on norepinephrine-induced activation of adenylyl cyclase of rat pineal gland. Fed. Proc. 26:765, 1967.
6. Weiss, B. and Costa, E.: Postjunctional localization of adenylyl cyclase activity in rat brain. 7th Intl. Cong. Biochem., August, 1967, Tokyo, Japan, Abstr. #J373, p. 1040.
7. Weiss, B.: Differences in the stimulatory effects of norepinephrine (NE) and sodium fluoride on adenylyl cyclase (AC) of pineal gland and cerebellum. Fed. Proc. 27:752, 1968.
8. Weiss, B. and Crayton, J.: Ovarian regulation of the norepinephrine-sensitive adenylyl cyclase system of rat pineal gland. Fed. Proc. 28:615, 1970.
9. Ebadi, M.S., Weiss, B. and Costa, E.: A sensitive and specific method for assaying cyclic 3',5'-AMP in rat pineal gland. Fed. Proc. 29:263, 1970.
10. Ebadi, M.S., Weiss, B. and Costa, E.: Diurnal periodicity of cyclic 3',5'-adenosine monophosphate in rat pineal gland. Pharmacologist 12:290, 1970.
11. Weiss, B.: A rapid microassay of phosphodiesterase activity. Trans. Am. Soc. Neurochem. 2:117, 1971.
12. Weiss, B., Uzunov, P., Strada, S. and Lehne, R.: Postnatal ontogenesis of adenylyl cyclase, phosphodiesterase and cyclic 3',5'-adenosine monophosphate in rat brain and pineal gland. 25th Intl. Cong. Physiol. Sci., Munich, Germany, p. 600, 1971.
13. Uzunov, P. and Weiss, B.: Inhibition by phenothiazine tranquilizers of the cyclic 3',5'-AMP system of rat brain. Fed. Proc. 30:330, 1971.
14. Guidotti, A., Weiss, B. and Costa, E.: Effect of isoproterenol (ISP) on the concentration of cyclic 3',5'-AMP (cAMP) in mouse parotid gland. Pharmacologist 13:256, 1971.

15. Strada, S.J., Uzunov, P. and Weiss, B.: Increased sensitivity to norepinephrine (NE) of the cyclic 3',5'-AMP (cAMP) system of rat brain following 6-hydroxydopamine (6-HDM). Pharmacologist 13:257, 1971.
16. Uzunov, P. and Weiss, B.: Effect of psychotomimetic drugs on the cyclic 3',5'-AMP system of rat brain. Pharmacologist 13:257, 1971.
17. Uzunov, P. and Weiss, B.: Separation and characterization of multiple adenosine 3',5'-monophosphate phosphodiesterase activities of rat brain. Fed. Proc. 31:514, 1972.
18. Uzunov, P., Shein, H.M. and Weiss, B.: Evidence for distinct forms of cyclic 3',5'-AMP phosphodiesterase in rat cerebellum and in cloned astrocytoma and neuroblastoma cells. 5th Intl. Cong. Pharmacol., San Francisco, Ca., p 239, 1972.
19. Strada, S.J. and Weiss, B.: Increased sensitivity of the cyclic 3',5'-AMP system of rat pineal gland induced by decreased sympathetic nerve activity. Soc. Neurosci., 1972.
20. Strada, S.J., Uzunov, P. and Weiss, B.: Distribution and ontogenetic development of multiple phosphodiesterase activities of rat brain. Fed. Proc., 30:514, 1972.
21. Weiss, B., Shein, H.M. and Uzunov, P.: Induction by norepinephrine of a specific form of cyclic 3',5'-AMP phosphodiesterase in cloned rat astrocytoma cells (C-2A). Fed. Proc., 32:679, 1973.
22. Fertel, R., Uzunov, P. and Weiss, B.: Selective activation and inhibition of the multiple forms of cyclic 3',5'-AMP phosphodiesterase of rat brain. Fed. Proc. 32:679, 1973.
23. Fertel, R. and Weiss, B.: A selective microassay of guanosine 3',5'-monophosphate (cyclic GMP) phosphodiesterase activity. Pharmacologist 15:157, 1973.
24. Fertel, R. and Weiss, B.: Effects of drugs on the cyclic nucleotide phosphodiesterase of rat lung. Fed. Proc. 33:2033, 1974.
25. Greenberg, L.H., Conner, R.L. and Weiss, B.: Cyclic AMP phosphodiesterase activity of *Tetrahymena pyriformis*: Apparent induction by theophylline. Fed. Proc. 34, 1975.
26. Levin, R.M. and Weiss, B.: On the mechanism of the inhibition of brain cyclic AMP phosphodiesterase by psychotropic agents. Pharmacologist 17:233, 1975.
27. Hait, W.N. and Weiss, B.: Increased activity of cyclic AMP and cyclic GMP phosphodiesterase in lymphocytic leukemia. Clin. Res. 595A, 1975.
28. Hait, W.N. and Weiss, B.: Characteristics of cyclic nucleotide phosphodiesterase of normal and leukemic lymphocytes. Fed. Proc. 35:610, 1976.
29. Greenberg, L.H. and Weiss, B.: Activatable phosphodiesterases in various areas of rat brain. Am. Soc. Neurochem. 7:115, 1976.

30. Levin, R.M. and Weiss, B.: Binding of antipsychotic agents to the cyclic nucleotide activator. Fed. Proc. 36:619, 1977.
31. Levin, R.M. and Weiss, B.: Specificity of binding of antipsychotics to the activator of cyclic nucleotide phosphodiesterase. Pharmacologist 19:203, 1977.
32. Greenberg, L.H., Dix, R.K. and Weiss, B.: Age-related decrease in beta-adrenergic receptors in rat brain. Am. Ageing Assoc., New York, 1977.
33. Greenberg, L.H. and Weiss, B.: Effect of age on the ability of beta-adrenergic receptors of rat brain to develop sub- and supersensitivity. Fed. Proc. 37:878, 1978.
34. Cantor, E. and Weiss, B.: Post-natal development of the beta-adrenergic receptor and the calcium-dependent activator of adenylate cyclase and phosphodiesterase in rat pineal gland. Fed. Proc. 37:524, 1978.
35. Cantor, E. and Weiss, B.: Regional development of beta-adrenergic receptors in rat brain. Soc. Neurosci. 4, 1978.
36. Wallace, T.L., Levin, R.M. and Weiss, B.: Comparison of the properties of the multiple forms of cyclic AMP phosphodiesterase of rat brain and heart based on their sensitivity to chlorpromazine. Pharmacologist 20:232, 1978.
37. Levin, R.M. and Weiss, B.: Selective inhibition of an activable ATPase by trifluoperazine. Pharmacologist 20:195, 1978.
38. Greenberg, L.H. and Weiss, B.: Reserpine-induced increased in the density of beta-adrenergic receptors in aging rat brain. 7th Intl. Cong. Pharmacol. 2:863, 1978.
39. Winchurch, R.A., Hait, W. and Weiss, B.: Quantitative and qualitative differences in cyclic AMP phosphodiesterase of murine T and B lymphocytes. Am. Assoc. Immunol., 37:360, 1978.
40. Moyer, J.A., Frazer, A., Weiss, B., Greenberg, L.H. and Mendels, J.: Noradrenergic responsiveness in rat pineal gland after single or repeated administration of desmethylimipramine. Soc. Neurosci. 5:657, 1979.
41. Cantor, E.H., Greenberg, L.H. and Weiss, B.: Increased beta-adrenergic receptors in rat pineal gland after sympathectomy. Trans. Am. Soc. Neurochem. 10:22, 1979.
42. Cimino, M., Prozialeck, W. and Weiss, B.: Irreversible binding of trifluoperazine to calmodulin by photoaffinity labeling. Pharmacologist 21:240, 1979.
43. Weiss, B., Greenberg, L.H. and Cantor, E.: Denervation supersensitivity and beta-adrenergic receptors as a function of age. Proc. Ist Intl. Colloquium on Receptors, Capri, Italy, 1979.

44. Puglia, C., Powell, S. and Weiss, B.: Decreased ability of senescent rats to maintain body temperature during cold exposure. Fed. Proc. 39:509, 1980.
45. Heydorn, W.E., Weiss, B. and Frazer, A.: Electrical stimulation of the superior cervical ganglia increases the concentration of cyclic AMP of rat pineal gland. Soc. Neurosci. 6:845, 1980.
46. Clark, M.B. and Weiss, B.: Factors affecting the development of pineal beta-adrenergic receptors in culture. Soc. Neurosci. 6:597, 1980.
47. Barnette, M.S. and Weiss, B.: Effect of neuropeptides on calmodulin-induced activation of phosphodiesterase. Soc. Neurosci. 6:621, 1980.
48. Heydorn, W.E. and Weiss, B. and Frazer, A.: Effect of treatment with desmethylimipramine (DMI) on the rise of cyclic AMP in rat pineal gland following stimulation of its sympathetic input. Pharmacologist 22:298, 1980.
49. Weiss, B., Prozialeck, W., Cimino, M., Barnette, M.S. and Wallace, T.L.: Modification of calmodulin activity by antipsychotic drugs and polypeptides. N.Y. Acad. Sci., 1981.
50. Greenberg, L.H. and Weiss, B.: Changes in catecholamine receptors of rat brain during the estrus cycle. 8th Intl. Cong. Pharmacol., Tokyo, Japan, 1981.
51. Greenberg, L.H. and Weiss, B.: Estrogen reduces beta-adrenergic receptors of rat pineal gland and other brain areas. Fed. Proc. 40:260, 1981.
52. Weiss, B., Heydorn, W., Greenberg, L. and Frazer, A.: Modulation of the beta-adrenergic receptor-adenylate cyclase system following acute and repeated treatment with antidepressants. Intl. Symp. on Typical and Atypical Antidepressants, Taormina, Italy, 1981.
53. Greenberg, L.H. and Weiss, B.: Neuroendocrine control of catecholaminergic receptors. Proc. Intl. Symp. on Aging Brain and Ergot Alkaloids, Rome, Italy, pp. 18-19, 1981.
54. Wallace, T.L., Earl, C.Q., Habas, J.E. and Weiss, B.: Chlorpromazine binds to and inhibits calmodulin in rat brain. Soc. Neurosci. 7:104, 1981.
55. Prozialeck, W.C. and Weiss, B.: Inhibition of calmodulin by phenothiazines: structure-activity relationships. Fed. Proc. 41:1566, 1982.
56. Earl, C.Q., Prozialeck, W.C. and Weiss, B.: Inhibition of calmodulin activity by alpha-adrenergic antagonists. Fed. Proc. 41:1565, 1982.
57. Greenberg, L.H., Brunswick, D. and Weiss, B.: Impaired recovery of brain beta-adrenergic receptors in aged rats following desmethylimipramine-induced subsensitivity. Soc. Neurosci. 8:659, 1982.
58. Barnette, M.S. and Weiss, B.: Interaction of neuropeptides with calmodulin. ACNP Meeting, December, 1982.

59. Weiss, B., Earl, C.Q. and Prozialeck, W.C.: Pharmacological regulation of calmodulin activity. ACNP Meeting, December, 1982.
60. Weiss, B.: Calmodulin: Function and pharmacological regulation. Amer. Chem. Soc., 17th Middle Atlantic Regional Meeting, p. 141, April, 1983.
61. Zhou, L-W., Greenberg, L.H. and Weiss, B.: Impaired recovery of alpha₁-adrenergic receptors in brain of aged rats. Fed. Proc., 42:381, 1983.
62. Prozialeck, W.C., Wallace, T.L. and Weiss, B.: Chlorpromazine-linked calmodulin: A novel calmodulin antagonist. Fed. Proc., 42:1087, 1983.
63. Hait, W.N., Cadman, E., Benz, C., Cole, J. and Weiss, B.: Inhibition of growth of L1210 leukemic cells by inhibitors of cyclic nucleotide phosphodiesterase (PDE) and calmodulin (CAL). Proc. Am. Assoc. Cancer Res. 25:50, 1983.
64. Barnette, M.S. and Weiss, B.: Inhibition of calmodulin activity by neuropeptides. Pharmacologist 25:183, 1983.
65. Zhou, L-W., Freilich, J.S., Weiss, B. and Greenberg, L.H.: Impaired recovery of alpha 1 and alpha 2-adrenergic receptors in brain of aged rats following their irreversible inhibition. Altered Endocrine Status During Aging, pp 201-202, 1984.
66. Weiss, B., Barnette, M.S. Paikowsky, S. and Kaiser, C.: Irreversible inhibition of calmodulin (CM) activity by fluphenazine-N-mustard (FNM). Fed. Proc., 43:765, 1984.
67. Weiss, B.: Calmodulin: function and pharmacological regulation. In: Calcium Metabolism and Nervous System, ed Canonico, P.L., April 28-29, 1984.
68. Thermos, K. and Weiss, B.: Irreversible interaction of fluphenazine (F) and Fluphenazine-N-mustard (FNM) with [³H]spiroperidol binding sites in vivo and in vitro. Fed. Proc. 44:1828, 1985.
69. Weiss, B., Goodale, D., Thermos, K. and Winkler, J.: Modulation of dopaminergic receptors. Fourth Capo Boi Conference on Neuroscience, pp 121-122, 1985.
70. Goodale, D.B., Jacobi, A.G. McN., Winkler, J.D. and Weiss, B.: Rapid stereotaxic injections into mouse striatum using a plastic mold. Soc. Neurosci. 11:772, 1985.
71. Thermos, K., Winkler, J.D., Goodale, D.B. and Weiss, B.: Effects of an irreversible dopaminergic ligand, fluphenazine-N-mustard (FNM), on dopaminergic behavior in supersensitive mice. Soc. Neurosci. 11:923, 1985.
72. Winkler, J.D. and Weiss, B.: Reversal of supersensitive apomorphine-induced turning behavior in mice by continuous exposure to apomorphine. Abst. IV World Cong. Biol. Psychiatry, p 109, 1985.

73. Allen, D., Goldman, W. and Weiss, B.: Elevated phosphodiesterase activity in human CSF following acute aneurysmal subarachnoid hemorrhage: clinical significance and prognostic value. Congress Neurological Surgery, Honolulu, Hawaii, Sept., 1985.
74. Winkler, J.D. and Weiss, B.: Continuous exposure of mice to apomorphine reverses the supersensitive rotational behavior induced by dopaminergic agonists. Fed. Proc., 45:322, 1986.
75. Winkler, J.D. and Weiss, B.: Effect of continuous exposure to apomorphine in dopaminergically supersensitive mice on the binding of [³H]spiroperidol and the rotational behavior induced by dopaminergic agonists. Soc. Neurosci., 12:25, 1986.
76. Thermos, K., Prozialeck, W. and Weiss, B.: Isolation of sites in mouse striatum irreversibly labeled with fluphenazine-N-mustard (FNM) and apomorphine. Soc. Neurosci., 12:989, 1986.
77. Goodale, D.B., Jacobi, A.G.M., and Weiss, B.: Selective D-1 induced supersensitivity following multiple unilateral MPTP intrastriatal injections in mice. Soc. Neurosci., 12:193, 1986.
78. Roberts-Lewis, J.M., Baldino, F., Jr., Krause, R., Chesselet, M.-F., Weiss, B. and Lewis, M.E.: In situ hybridization histochemistry of calmodulin mRNA in rat brain. Soc. Neurosci., 12:1397, 1986.
79. Winkler, J.D., Thermos, K. and Weiss, B.: Differential effects of the irreversible dopaminergic antagonist, fluphenazine-N-mustard, on D₁ and D₂ dopaminergic behavior and radioligand binding in supersensitive mice. 15th Congress Collegium Intl. Neuro-Psychopharmacol., San Juan, Puerto, Rico, 1986.
80. Roberts-Lewis, J.M., Krause, R., Weiss, B. and Lewis, M.E. Distribution of calmodulin mRNA in rat brain using in situ hybridization. Fed. Proc., 46:397, 1987.
81. Lewis, M.E., Tyrrell, D.F., Jr., Roberts-Lewis, J. M., Weiss, B., Manning, R.W. and Davis, L. G.: Isolation of cDNA clones encoding rat brain calmodulin. Soc. Neurosci., 13:560, 1987.
82. Winkler, J.D., Callison, K., Cass, S. Weiss, B.: Selective down regulation of D₁ dopaminergic mediated rotational behavior in supersensitive mice. Soc. Neurosci., 13:199, 1987.
83. Cimino, M., Callison, K. and Weiss, B.: Distribution of calmodulin mRNA in developing rat brain. Internat. J. Develop. Neurosci., Abs. p. 58, 1988.
84. Weiss, B., Cimino, M., Winkler, J., Callison, K. and Cass, S.: Behavioral, biochemical and molecular biological correlates of modulating dopaminergic responses. Neurochem. Pharmacol., pp. 43-45, 1988.
85. Cimino, M., Cattabeni, F. and Weiss, B.: Regulation of calmodulin, enkephalin and somatostatin mRNAs in developing rat brain using in situ hybridization histochemistry. Soc. Ital. Neurosci., 1988.

86. Zhang, S.-P., Prozialeck, W. and Weiss, B.: Selective inhibition of calmodulin (CM)-dependent enzymes by phenothiazine-CM adducts. Pharmacologist, A-89, 1988.
87. Cimino, M., Chen, F., and Weiss, B.: Comparative ontogenetic development of the mRNA's for calmodulin (CM), proenkephalin (ENK) and prosomatostatin (SS). Pharmacologist, A-23, 1988.
88. Weiss, B., Cimino, M., Roberts-Lewis, J. and Lewis, M.E.: Development and regulation of calmodulin mRNA in rat brain using in situ hybridization histochemistry. Molecular Neurobiology: Proc. First NIMH Conf., eds. S. Zalcman and R. Scheller, Santa Barbara, CA., NIMH, p.347, 1989.
89. Chen, J.F., Cimino, M. and Weiss, B.: Comparative regional distribution in rat brain of the mRNAs for two calcium-binding proteins: Calmodulin and S-100 protein. FASEB J., 3:A602, 1989.
90. Zhou, L.-W., Milligan, C. and Weiss, B.: Down regulation of stereotypy and development of locomotor behavior following the continuous administration of the dopamine D₂ agonist quinpirole in mice. FASEB J., 3:A1045, 1989.
91. Bai, G., Chen, J.F. and Weiss, B.: Nerve growth factor (NGF) increases calmodulin (CaM) mRNA and CaM activity in PC12 cells. Soc. Neurosci., 15:501, 1989.
92. Szele, F., Chen, J.F., Bai, G. and Weiss, B.: Distribution of the D₂ dopamine receptor mRNA in mouse brain: In situ hybridization studies using a novel oligonucleotide probe. Soc. Neurosci., 15:500, 1989.
93. Weiss, B., Zhou, L.-W., Chen, J.F., Szele, F. and Bai, G.: Distribution and modulation of the D₂ dopamine receptor mRNA in mouse brain: Molecular and behavioral correlates. Sixth Capo Boi Conference on Neuroscience, 1989.
94. Zhou, L.-W., Zhang, S.-P., Welsh, S. and Weiss, B.: Triazolam blocks the behavior but not the down regulation of dopamine receptors induced by continuous exposure to quinpirole in 6-hydroxydopamine lesioned mice. FASEB J., 4:A458, 1990.
95. Bai, G. and Weiss, B.: Nerve growth factor (NGF) induces a differential increase in the multiple mRNA's for calmodulin in PC12 cells. Soc. Neurosci., 16:343, 1990.
96. Weiss, B., Chen, J.-F., Zhang, S.-P. and Zhou, L.-W.: Alterations in the mRNA's for the different subtypes of the D₂ dopamine receptor in rat brain during development and aging. In Dopamine Systems and their Regulation, Como, Italy, 1990.
97. Zhou, L.-W., Zhang, S.-P., Welsh, S. and Weiss, B.: A novel model for reversing behavioral dopaminergic supersensitivity without producing an initial exacerbation of dopaminergic behavior. Am. Col. Neuropsychopharmacol. p.224, 1990.
98. Zhou, L.-W., Zhang, S.-P., Connell, T.A. and Weiss, B.: AF64A lesions of mouse striatum cause rotational behavior and a reduction in D₂ dopamine receptors and D₂ dopamine receptor mRNA. FASEB J., 5:A879, 1991.

99. Bai, G., Nichols, R.A. and Weiss, B.: Cyclic AMP increases the expression of selective calmodulin genes in PC12 cells. FASEB J., 5:A450, 1991.
100. Chen, J.-F., Zhou, L.-W. and Weiss, B.: Selective down-regulation of D₂ dopamine receptor mRNA in mouse striatum following continuous infusion with the D₂ dopamine agonist quinpirole. Soc. Neurosci., 17:917, 1991.
101. Zhou, L.-W., Zhang, S.-P., Connell, T.A. and Weiss, B.: Cholinergic - dopaminergic interactions in mouse striatum: Molecular and behavioral correlates. Am. Col. Neuropsychopharmacol. p.199, 1991.
102. Zhang, S.-P., Natsukari, N., Nichols, R.A. and Weiss, B.: Localization of calmodulin (CaM) and the multiple CaM mRNAs in differentiated PC12 cells. Soc. Neurosci. 18:236, 1992.
103. Natsukari, N., Zhang, S.-P., Nichols, R.A. and Weiss, B.: Alteration in the levels of calmodulin-binding proteins during differentiation of PC12 cells. Soc. Neurosci., 18:236, 1992.
104. Chen, J.-F., Qin, Z.-H. and Weiss, B.: Irreversible blockade of dopamine receptors by fluphenazine-N-mustard increases D₂ dopamine receptor mRNA and proenkephalin mRNA in rat striatum. Soc. Neurosci., 18:398, 1992.
105. Qin, Z.-H., Chen, J.-F. and Weiss, B.: Denervation of mouse striatum decreases D₁ receptor mRNA and the rate of synthesis of D₁ receptors and increases D₂ receptor mRNA and the rate of synthesis of D₂ receptors. Soc. Neurosci., 18:1536, 1992.
106. Weiss, B., Zhang, S.-P., Natsukari, N. and Nichols, R.A.: Distribution and role of the multiple calmodulin mRNAs in differentiated PC12 cells using antisense oligodeoxynucleotides. INSERM/NIH Conference on "Antisense Oligonucleotides and Ribonucleases H," Abst. 38, Arcachon, France, 1992.
107. Zhou, L.-W., Zhang, S.-P. and Weiss, B.: Administration of an oligodeoxynucleotide antisense to the D₂ dopamine receptor mRNA inhibits the rotational behavior induced by the D₂ dopamine receptor agonist quinpirole in 6-hydroxydopamine-lesioned mice. Am. Col. Neuropsychopharmacol., 1992.
108. Qin, Z.-H., Zhou, L.-W. and Weiss, B.: D₂ dopamine receptor mRNA is altered to a greater extent by blockade of glutamate receptors than by blockade of dopamine receptors in mouse brain. Soc. Neurosci., 19:498, 1993.
109. Zhang, S.-P., Qin, Z.-H. and Weiss, B.: Dopaminergic and glutamatergic blocking drugs differentially regulate glutamate acid decarboxylase (GAD) mRNA in mouse brain. Soc. Neurosci., 19:498, 1993.
110. Chen, J.-F., Zhang, S.-P., Connell, T.A., Zhou, L.-W. and Weiss, B.: Clozapine produces different effects from those of fluphenazine-N-mustard (FNM) on receptors and mRNAs associated with dopaminergic and opioid peptidergic systems of mouse brain. Soc. Neurosci., 19:1383, 1993.

111. Zhou, L.-W., Zhang, S.-P., Qin, Z.-H. and Weiss, B.: Antisense oligodeoxynucleotide administered in vivo inhibits D₂ dopamine receptor-mediated behavior, D₂ dopamine receptors and D₂ dopamine receptor mRNA in mouse striatum. Soc. Neurosci., 19:428, 1993.
112. Weiss, B., Zhou, L.-W. and Zhang, S.-P.: Antisense strategies for modulating dopaminergic behavior. Am. Psychol. Assn., 1994.
113. Weiss, B., Zhou, L.-W. and Zhang, S.-P.: Behavioral and molecular effects of dopamine receptor antisense oligodeoxynucleotides administered in vivo. Neuropsychopharmacology, 10:801S, 1994.
114. Weiss, B., Zhou, L.-W. and Zhang, S.-P.: D₁ and D₂ dopamine receptor antisense oligodeoxynucleotides alter dopaminergic behavior. Dopamine 94, Int'l Congress of Pharmacology, 1994.
115. Nichols, R.A., Zhang, S.-P. and Weiss, B.: Assessing the role of calmodulin in nerve cell differentiation using antisense oligodeoxynucleotides specific for calmodulin mRNA. Neuropsychopharmacology, 10:799S, 1994.
116. Zhou, L.-W., Zhang, S.-P. and Weiss, B.: Oligodeoxynucleotide antisense to D₁ dopamine receptor mRNA inhibits D₁ receptor-mediated behaviors. Soc. Neurosci., 20:908, 1994.
117. Qin, Z.-H., Zhang, S.-P., Zhou, L.-W., Wang, Y. and Weiss, B.: D₂ dopamine receptor antisense oligodeoxynucleotide inhibits the rate of synthesis of D₂ receptors and delays the restoration of D₂ receptor-mediated behaviors in mice after irreversible inactivation of D₂ receptors. Soc. Neurosci., 20:908, 1994.
118. Zhang, S.-P., Nichols, R.A. and Weiss, B.: Oligodeoxynucleotides antisense to calmodulin mRNAs inhibit proliferation and NGF-induced differentiation of PC12 cells. Soc. Neurosci., 20:1316, 1994.
119. Davidkova, G., Zhang, S.-P., Nichols, R. and Weiss, B.: Transfection of PC12 cells with calmodulin antisense and sense RNA alters their growth and differentiation. FASEB J., 9:A382, 1995.
120. Weiss, B., Zhou, L.-W. and Zhang, S.-P.: Antisense strategies in neurobiology: In Practical Approaches to the Regulation of Gene Expression. Univ. Oxford, 1995.
121. Davidkova, G., Zhang, S.-P., Nichols, R. and Weiss, B.: Altering calmodulin gene expression influences the proliferation and differentiation of PC12 cells. Internat. Conf. on "Therapeutic Oligonucleotides: From Cell to Man". Seillac, France, 1995.
122. Zhang, S.-P., Zhou, L.-W., Lin, R.C.S. and Weiss, B.: Uptake and distribution of fluorescein-labeled D₂ dopamine receptor mRNA antisense oligodeoxynucleotide in mouse brain. Soc. Neurosci., 21:364, 1995.

123. Weiss, B., Davidkova, G., Zhou, L.-W., Zhang, S.P. and Morabito, M.: Expression vector encoding a D₂ dopamine receptor antisense RNA produces long-term inhibition of D₂ dopamine receptor-mediated behaviors in mice. College on Problems of Drug Dependence, p. 147, 1996.
124. Davidkova, G., Zhou, L.-W., Zhang, S.-P., Morabito, M. and Weiss, B.: Transfection of D₂ dopamine receptor antisense RNA plasmid vector *in vitro* and *in vivo*. Soc. Neurosci., 22:1319, 1996.
125. Zhou, L.-W., Davidkova, G., Zhang, S.-P., Morabito, M. and Weiss, B.: Biochemical and behavioral effects of a D₂ dopamine receptor antisense RNA vector transfected in mouse brain. Soc. Neurosci., 22:1318, 1996.
126. Hou, W.-F., Zhang, S.-P., Davidkova, G., Nichols, R.A. and Weiss, B.: Antisense oligodeoxynucleotides directed to individual calmodulin gene transcripts inhibit the proliferation of PC12 cells. Soc. Neurosci., 22:1736, 1996.
127. Neff, N.H., Cho, S., Weiss, B. and Hadjiconstantinou, M.: Dopamine receptors and the regulation of tyrosine hydroxylase and aromatic L-amino acid decarboxylase. Soc. Neurosci., 22:1316, 1996.
128. Davidkova, G., Zhou, L.-W., Zhang, S.-P. and Weiss, B.: A plasmid vector producing D₂ dopamine receptor antisense RNA inhibits D₂ receptor-mediated behaviors in mice. Am. Coll. Clin. Pharmacol., 1996.
129. Weiss, B., Zhou, L.-W., Davidkova, G., Zhang, S.-P., and Morabito, M.: D2 dopamine antisense RNA vector induces long-term inhibition of D2 dopamine receptor-mediated behaviors. Allegheny-Singer Conference. 1996.
130. Weiss, B., Davidkova, G., Zhang, S.-P. and Zhou, L.-W.: Gene antisense therapy of D₂ dopamine receptor-mediated neuropsychiatric disorders. In: Antisense Oligonucleotide Gene Knockout in the Nervous System--Practical Approaches to the Regulation of Gene Expression: Progress in Neuroscience. University of Oxford, Oxford, England. pp 7-8, 1997.
131. Davidkova, G., Zhou, L.-W., Morabito, M., Zhang, S.-P. and Weiss, B.: Duration, localization and antisense mechanism of a D₂ dopamine antisense RNA expression vector in mouse brain. Soc. Neurosci., 23: 1775, 1997.
132. Zhou, L.-W., Davidkova, G., Morabito, M., Zhang, S.-P. and Weiss, B.: D₂ dopamine antisense RNA expression vector, unlike haloperidol, produces long-term inhibition of D₂-mediated behaviors without causing upregulation of D₂ receptors in mice. Soc. Neurosci., 22: 1775, 1997.
133. Weiss, B., Zhou, L.-W., and Davidkova, G.: Antisense RNA generation vectors as novel tools to study and treat diseases. Fourth National Congress of Pharmacology: The Challenges in the Face of Pharmacology on the Verge of the 21st Century. Sofia, Bulgaria. p.19, 1997.
134. Weiss, B., Zhou, L.-W. and Davidkova, G.: Antisense RNA generating vector produces long-term inhibition of D₂ dopamine receptors. Am. Col. Neuropsychopharmacol. 36: 1997.

OTHER PUBLISHED WORKS

Web site: **HISTORICAL AND COMMEMORATIVE MEDALS**

Copyright © 2003 Benjamin Weiss

<http://www.historicalartmedals.com/>

Medallic History of Religious and Racial Intolerance: Medals as Instruments for Promoting Bigotry.

<http://www.kunstpedia.com/articles/373/1/Medallic-History-of-Religious-and-Racial-Intolerance--Medals-as-instruments-for-promoting-bigotry/Page1.html>

OTHER HONORS:

Listed among the 1000 scientists most cited from 1965 to 1978.

Reference: Garfield, E. The 1,000 contemporary scientists most-cited 1965-1978. The list and introduction. Current Contents (41):pp. 5-14, 12 October 1981.

One of the published articles was cited as a Citation Classic, being among the 100 (number 31 on the list) most cited from 1961-1982, out "Of the millions of papers cited during this period"...

Ref: Garfield, E. The Articles most cited in 1961-1982. 3. Another All-Time Citation Classics. Current Contents, No. 35, pp. 3-9, 1984.

Establishment of the **Benjamin Weiss Scholarship in Pharmacology and Physiology**, Drexel University College of Medicine, 2006.